WO2021177279A1 - 高活性nk細胞の処理方法 - Google Patents
高活性nk細胞の処理方法 Download PDFInfo
- Publication number
- WO2021177279A1 WO2021177279A1 PCT/JP2021/007863 JP2021007863W WO2021177279A1 WO 2021177279 A1 WO2021177279 A1 WO 2021177279A1 JP 2021007863 W JP2021007863 W JP 2021007863W WO 2021177279 A1 WO2021177279 A1 WO 2021177279A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- highly active
- thawing
- hours
- medium
- Prior art date
Links
- 210000000822 natural killer cell Anatomy 0.000 title claims abstract description 167
- 238000000034 method Methods 0.000 title claims abstract description 116
- 210000004027 cell Anatomy 0.000 claims abstract description 366
- 238000010257 thawing Methods 0.000 claims abstract description 114
- OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 claims abstract description 44
- 238000005138 cryopreservation Methods 0.000 claims abstract description 35
- 238000011282 treatment Methods 0.000 claims abstract description 24
- 239000007788 liquid Substances 0.000 claims abstract description 22
- 239000003613 bile acid Substances 0.000 claims abstract description 8
- 238000000338 in vitro Methods 0.000 claims abstract description 8
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims abstract description 5
- 239000002904 solvent Substances 0.000 claims description 87
- 239000000243 solution Substances 0.000 claims description 75
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 43
- 239000011780 sodium chloride Substances 0.000 claims description 24
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M potassium chloride Inorganic materials [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 23
- AEQDJSLRWYMAQI-UHFFFAOYSA-N 2,3,9,10-tetramethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline Chemical compound C1CN2CC(C(=C(OC)C=C3)OC)=C3CC2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-UHFFFAOYSA-N 0.000 claims description 14
- 239000000176 sodium gluconate Substances 0.000 claims description 14
- 235000012207 sodium gluconate Nutrition 0.000 claims description 14
- 229940005574 sodium gluconate Drugs 0.000 claims description 14
- 239000001103 potassium chloride Substances 0.000 claims description 13
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 11
- 239000008103 glucose Substances 0.000 claims description 11
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L magnesium chloride Substances [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 11
- 239000001632 sodium acetate Substances 0.000 claims description 11
- 235000017281 sodium acetate Nutrition 0.000 claims description 11
- 235000011164 potassium chloride Nutrition 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 7
- 238000004113 cell culture Methods 0.000 claims description 6
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims description 5
- 229910001424 calcium ion Inorganic materials 0.000 claims description 5
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 238000003693 cell processing method Methods 0.000 claims 1
- 239000002609 medium Substances 0.000 abstract description 110
- 238000007710 freezing Methods 0.000 abstract description 43
- 230000008014 freezing Effects 0.000 abstract description 41
- 230000000694 effects Effects 0.000 abstract description 30
- 230000004083 survival effect Effects 0.000 abstract description 5
- 239000006143 cell culture medium Substances 0.000 abstract 1
- FVVLHONNBARESJ-NTOWJWGLSA-H magnesium;potassium;trisodium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;acetate;tetrachloride;nonahydrate Chemical compound O.O.O.O.O.O.O.O.O.[Na+].[Na+].[Na+].[Mg+2].[Cl-].[Cl-].[Cl-].[Cl-].[K+].CC([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O FVVLHONNBARESJ-NTOWJWGLSA-H 0.000 description 71
- 238000011084 recovery Methods 0.000 description 52
- 230000035899 viability Effects 0.000 description 48
- 230000001472 cytotoxic effect Effects 0.000 description 45
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 43
- 235000002639 sodium chloride Nutrition 0.000 description 41
- 238000012258 culturing Methods 0.000 description 38
- 239000002953 phosphate buffered saline Substances 0.000 description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 28
- YXHLJMWYDTXDHS-IRFLANFNSA-N 7-aminoactinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=C(N)C=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 YXHLJMWYDTXDHS-IRFLANFNSA-N 0.000 description 23
- 108700012813 7-aminoactinomycin D Proteins 0.000 description 23
- 241000282414 Homo sapiens Species 0.000 description 22
- 210000002966 serum Anatomy 0.000 description 22
- 239000012895 dilution Substances 0.000 description 21
- 238000010790 dilution Methods 0.000 description 21
- BHTRKEVKTKCXOH-LBSADWJPSA-N tauroursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)CC1 BHTRKEVKTKCXOH-LBSADWJPSA-N 0.000 description 20
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 19
- BHTRKEVKTKCXOH-UHFFFAOYSA-N Taurochenodesoxycholsaeure Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)CC2 BHTRKEVKTKCXOH-UHFFFAOYSA-N 0.000 description 19
- 238000004458 analytical method Methods 0.000 description 17
- 210000004369 blood Anatomy 0.000 description 17
- 239000008280 blood Substances 0.000 description 17
- 238000005259 measurement Methods 0.000 description 17
- 229950009215 phenylbutanoic acid Drugs 0.000 description 17
- 238000007447 staining method Methods 0.000 description 17
- -1 oxo acid salt Chemical class 0.000 description 16
- 239000012980 RPMI-1640 medium Substances 0.000 description 14
- 239000000203 mixture Substances 0.000 description 13
- 159000000000 sodium salts Chemical class 0.000 description 13
- 239000012979 RPMI medium Substances 0.000 description 12
- 239000000872 buffer Substances 0.000 description 12
- 230000007704 transition Effects 0.000 description 12
- 239000012636 effector Substances 0.000 description 11
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 10
- 210000005259 peripheral blood Anatomy 0.000 description 10
- 239000011886 peripheral blood Substances 0.000 description 10
- 238000000926 separation method Methods 0.000 description 10
- 206010028980 Neoplasm Diseases 0.000 description 9
- 238000007865 diluting Methods 0.000 description 9
- 230000003204 osmotic effect Effects 0.000 description 9
- 210000000130 stem cell Anatomy 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- 108091006905 Human Serum Albumin Proteins 0.000 description 8
- 102000008100 Human Serum Albumin Human genes 0.000 description 8
- 210000001744 T-lymphocyte Anatomy 0.000 description 8
- 238000002617 apheresis Methods 0.000 description 8
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 8
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 8
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 7
- 239000000654 additive Substances 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 239000012153 distilled water Substances 0.000 description 7
- 150000004820 halides Chemical class 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 7
- 229910017053 inorganic salt Inorganic materials 0.000 description 7
- 239000013642 negative control Substances 0.000 description 7
- 239000002504 physiological saline solution Substances 0.000 description 7
- 239000002994 raw material Substances 0.000 description 7
- 238000010186 staining Methods 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 230000000996 additive effect Effects 0.000 description 6
- 230000009089 cytolysis Effects 0.000 description 6
- 239000000644 isotonic solution Substances 0.000 description 6
- 229910001415 sodium ion Inorganic materials 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 5
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 5
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 5
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- 239000011324 bead Substances 0.000 description 5
- 229940050526 hydroxyethylstarch Drugs 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 159000000003 magnesium salts Chemical class 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 229910001414 potassium ion Inorganic materials 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000003223 protective agent Substances 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 238000001179 sorption measurement Methods 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 4
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 4
- 239000012981 Hank's balanced salt solution Substances 0.000 description 4
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 4
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 4
- 101000802660 Homo sapiens Histo-blood group ABO system transferase Proteins 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 4
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 4
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 4
- 159000000007 calcium salts Chemical class 0.000 description 4
- 150000001768 cations Chemical class 0.000 description 4
- 230000030833 cell death Effects 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 229960003957 dexamethasone Drugs 0.000 description 4
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 210000004700 fetal blood Anatomy 0.000 description 4
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 4
- 102000056538 human ABO Human genes 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 229960004584 methylprednisolone Drugs 0.000 description 4
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000012679 serum free medium Substances 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 3
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 3
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 3
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 3
- 102100025074 C-C chemokine receptor-like 2 Human genes 0.000 description 3
- 102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 description 3
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 3
- 235000005956 Cosmos caudatus Nutrition 0.000 description 3
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical class OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 3
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Natural products OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101000716068 Homo sapiens C-C chemokine receptor type 6 Proteins 0.000 description 3
- 101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 description 3
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 3
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 3
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 3
- 101000766306 Homo sapiens Serotransferrin Proteins 0.000 description 3
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 3
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 3
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 102000007562 Serum Albumin Human genes 0.000 description 3
- 108010071390 Serum Albumin Proteins 0.000 description 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Substances [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 3
- 230000005779 cell damage Effects 0.000 description 3
- 208000037887 cell injury Diseases 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 229940050410 gluconate Drugs 0.000 description 3
- 239000000174 gluconic acid Substances 0.000 description 3
- 235000012208 gluconic acid Nutrition 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 150000002772 monosaccharides Chemical class 0.000 description 3
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 2
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000025324 B-cell acute lymphoblastic leukemia Diseases 0.000 description 2
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 102100021260 Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Human genes 0.000 description 2
- 101000894906 Homo sapiens Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Proteins 0.000 description 2
- 102100022297 Integrin alpha-X Human genes 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 241000209094 Oryza Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- HLCFGWHYROZGBI-JJKGCWMISA-M Potassium gluconate Chemical compound [K+].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O HLCFGWHYROZGBI-JJKGCWMISA-M 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 159000000021 acetate salts Chemical class 0.000 description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 2
- 239000001099 ammonium carbonate Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 2
- 239000007640 basal medium Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000020411 cell activation Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 238000002659 cell therapy Methods 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 238000012136 culture method Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000004806 ferroptosis Effects 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 229940090044 injection Drugs 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 229910001425 magnesium ion Inorganic materials 0.000 description 2
- 239000007758 minimum essential medium Substances 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 235000011056 potassium acetate Nutrition 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000004224 potassium gluconate Substances 0.000 description 2
- 235000013926 potassium gluconate Nutrition 0.000 description 2
- 229960003189 potassium gluconate Drugs 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- LCOIAYJMPKXARU-VAWYXSNFSA-N salubrinal Chemical compound C=1C=CC2=CC=CN=C2C=1NC(=S)NC(C(Cl)(Cl)Cl)NC(=O)\C=C\C1=CC=CC=C1 LCOIAYJMPKXARU-VAWYXSNFSA-N 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 description 2
- 229960001661 ursodiol Drugs 0.000 description 2
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- DXOCDBGWDZAYRQ-UHFFFAOYSA-N (3alpha,5beta)-3-Hydroxy-7-oxocholan-24 -oic acid Natural products C1CC(O)CC2CC(=O)C3C4CCC(C(CCC(O)=O)C)C4(C)CCC3C21C DXOCDBGWDZAYRQ-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- GHCZAUBVMUEKKP-NHIHLBCISA-N 2-[[(4R)-4-[(3R,5S,7S,10S,13R,17R)-3,7-Dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]acetic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)C1C2C2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)CC1 GHCZAUBVMUEKKP-NHIHLBCISA-N 0.000 description 1
- BNXLUNVCHFIPFY-GUBAPICVSA-N 2-[[(4r)-4-[(3r,5s,7s,8r,9s,10s,13r,14s,17r)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]ethanesulfonic acid;dihydrate Chemical compound O.O.C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)CC1 BNXLUNVCHFIPFY-GUBAPICVSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- DXOCDBGWDZAYRQ-AURDAFMXSA-N 7-oxolithocholic acid Chemical compound C1C[C@@H](O)C[C@H]2CC(=O)[C@H]3[C@@H]4CC[C@H]([C@@H](CCC(O)=O)C)[C@@]4(C)CC[C@@H]3[C@]21C DXOCDBGWDZAYRQ-AURDAFMXSA-N 0.000 description 1
- 206010000871 Acute monocytic leukaemia Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 102100020715 Fms-related tyrosine kinase 3 ligand protein Human genes 0.000 description 1
- 101710162577 Fms-related tyrosine kinase 3 ligand protein Proteins 0.000 description 1
- 101000766307 Gallus gallus Ovotransferrin Proteins 0.000 description 1
- 108010007979 Glycocholic Acid Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 description 1
- 101000971513 Homo sapiens Natural killer cells antigen CD94 Proteins 0.000 description 1
- DGABKXLVXPYZII-UHFFFAOYSA-N Hyodeoxycholic acid Natural products C1C(O)C2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 DGABKXLVXPYZII-UHFFFAOYSA-N 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 102100025323 Integrin alpha-1 Human genes 0.000 description 1
- 108010041341 Integrin alpha1 Proteins 0.000 description 1
- 102000000510 Integrin alpha3 Human genes 0.000 description 1
- 108010041357 Integrin alpha3 Proteins 0.000 description 1
- 102000008607 Integrin beta3 Human genes 0.000 description 1
- 108010020950 Integrin beta3 Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 101150069255 KLRC1 gene Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- SMEROWZSTRWXGI-UHFFFAOYSA-N Lithocholsaeure Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 SMEROWZSTRWXGI-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 101100404845 Macaca mulatta NKG2A gene Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000035489 Monocytic Acute Leukemia Diseases 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 102100022682 NKG2-A/NKG2-B type II integral membrane protein Human genes 0.000 description 1
- 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 description 1
- RFDAIACWWDREDC-UHFFFAOYSA-N Na salt-Glycocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCC(O)=O)C)C1(C)C(O)C2 RFDAIACWWDREDC-UHFFFAOYSA-N 0.000 description 1
- 102100021462 Natural killer cells antigen CD94 Human genes 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 239000008156 Ringer's lactate solution Substances 0.000 description 1
- 102000005686 Serum Globulins Human genes 0.000 description 1
- 108010045362 Serum Globulins Proteins 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- WBWWGRHZICKQGZ-UHFFFAOYSA-N Taurocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)C(O)C2 WBWWGRHZICKQGZ-UHFFFAOYSA-N 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 102000016548 Vascular Endothelial Growth Factor Receptor-1 Human genes 0.000 description 1
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 108010076089 accutase Proteins 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 210000004504 adult stem cell Anatomy 0.000 description 1
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 1
- 235000012501 ammonium carbonate Nutrition 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940125644 antibody drug Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000004900 autophagic degradation Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- AYJRCSIUFZENHW-DEQYMQKBSA-L barium(2+);oxomethanediolate Chemical compound [Ba+2].[O-][14C]([O-])=O AYJRCSIUFZENHW-DEQYMQKBSA-L 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 208000026900 bile duct neoplasm Diseases 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 1
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000021186 dishes Nutrition 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 229940093181 glucose injection Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- RFDAIACWWDREDC-FRVQLJSFSA-N glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 description 1
- 229940099347 glycocholic acid Drugs 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229960001008 heparin sodium Drugs 0.000 description 1
- DKPMWHFRUGMUKF-KWXDGCAGSA-N hyocholic acid Chemical compound C([C@H]1[C@@H](O)[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 DKPMWHFRUGMUKF-KWXDGCAGSA-N 0.000 description 1
- DGABKXLVXPYZII-SIBKNCMHSA-N hyodeoxycholic acid Chemical compound C([C@H]1[C@@H](O)C2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 DGABKXLVXPYZII-SIBKNCMHSA-N 0.000 description 1
- 108010055790 immunoglobulin B Proteins 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 108010074108 interleukin-21 Proteins 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- SMEROWZSTRWXGI-HVATVPOCSA-N lithocholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 SMEROWZSTRWXGI-HVATVPOCSA-N 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- QWDJLDTYWNBUKE-UHFFFAOYSA-L magnesium bicarbonate Chemical compound [Mg+2].OC([O-])=O.OC([O-])=O QWDJLDTYWNBUKE-UHFFFAOYSA-L 0.000 description 1
- 239000002370 magnesium bicarbonate Substances 0.000 description 1
- 229910000022 magnesium bicarbonate Inorganic materials 0.000 description 1
- 235000014824 magnesium bicarbonate Nutrition 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000021597 necroptosis Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000000879 optical micrograph Methods 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 229940086066 potassium hydrogencarbonate Drugs 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 238000007781 pre-processing Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000011814 protection agent Substances 0.000 description 1
- 239000000941 radioactive substance Substances 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000007420 reactivation Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- WBWWGRHZICKQGZ-GIHLXUJPSA-N taurocholic acid Chemical compound C([C@@H]1C[C@H]2O)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@H](O)C1 WBWWGRHZICKQGZ-GIHLXUJPSA-N 0.000 description 1
- AWDRATDZQPNJFN-VAYUFCLWSA-N taurodeoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@@H](O)C1 AWDRATDZQPNJFN-VAYUFCLWSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- GHCZAUBVMUEKKP-UHFFFAOYSA-N ursodeoxycholic acid glycine-conjugate Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCC(O)=O)C)C1(C)CC2 GHCZAUBVMUEKKP-UHFFFAOYSA-N 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
- A01N1/0221—Freeze-process protecting agents, i.e. substances protecting cells from effects of the physical process, e.g. cryoprotectants, osmolarity regulators like oncotic agents
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0278—Physical preservation processes
- A01N1/0284—Temperature processes, i.e. using a designated change in temperature over time
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4613—Natural-killer cells [NK or NK-T]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/04—Preserving or maintaining viable microorganisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates to a method for cryopreserving cells having high cytotoxic activity.
- Non-Patent Document 1 Non-Patent Document 1
- Patent Document 1 As a method for preserving cells, a method of storing cells in a suspended state without freezing is known in the case of short-term storage (for example, Patent Document 1), and in the case of long-term storage, storage is performed by freezing.
- the method is known (for example, Patent Document 2).
- Patent Document 3 For freezing containing sodium salts, potassium salts, sugars, frost protection agents, and bicarbonates and / or carbonates, as cells are further frozen to give cells that maintain high viability even after thawing.
- Patent Document 3 The use of a solution has been studied.
- An object of the present invention is to provide a method for cryopreserving and thawing while maintaining high viability and high activity, which can be applied to highly active NK cells.
- the present invention provides: [1] Cell treatment method including the following steps: (1) Cells activated in vitro are collected in a medium for cell culture; (2) Suspend the collected cells in a solution for cryopreservation; (3) Freeze the suspended cells. [2] The method according to [1], wherein step (1) comprises treatment with a medium supplemented with any one selected from the group consisting of bile acids and phenylbutyric acid. [3] The method according to [1] or [2], which further comprises the following steps: (4) The cryopreserved cells are thawed and suspended in the thaw solvent I.
- thawing solvent I is an aqueous solution containing the following: ⁇ Sodium chloride 9.00-108 mM, ⁇ Sodium gluconate 2.30-27.7 mM, ⁇ Sodium acetate 2.70-32.5 mM, -Potassium chloride 0.496-5.96 mM, and-Magnesium chloride 0.148-1.78 mM.
- the thawing solvent I satisfies at least one of the following: ⁇ Does not contain calcium ions at a concentration of 0.423 mM or higher.
- -Glucose is not contained at a concentration of 5.55 mM or more, and lactate is not contained at a concentration of 27.7 mM or more.
- Liquid for suspending highly active NK cells including: ⁇ Sodium chloride 9.00-108 mM, ⁇ Sodium gluconate 2.30-27.7 mM, ⁇ Sodium acetate 2.70-32.5 mM, -Potassium chloride 0.496-5.96 mM, and-Magnesium chloride 0.148-1.78 mM.
- the solution according to [6] which is for suspending frozen highly active NK cells by suspending them in a solution for cryopreservation.
- a pharmaceutical composition comprising highly active NK cells, a solution for cryopreservation, and the solution described in [6].
- a method for producing a pharmaceutical composition containing cells which comprises the following steps: (1) Cells activated in vitro are collected in a medium for cell culture; (2) Suspend the collected cells in a solution for cryopreservation; (3) Freeze the suspended cells.
- step (1) comprises treatment with a medium supplemented with any one selected from the group consisting of bile acid and phenylbutyric acid.
- Flow cytometer analysis results of various cells after Mito-Ferro Green reaction are highly active NK cells have a high iron content, and it is suspected that Ferroptosis induction may occur.
- Lacto lactolin gel Continuation of Figure 1-3 Viability when thawing highly active NK cells. Viability improved when diluted with Plasma-Lyte A at the time of thawing, but Viability deteriorated when diluted with Plasma-Lyte A containing 40% Serum (human AB type serum). Viable cell number and viability (right) and cytotoxic activity (left) of highly active NK cells after standing for a certain period of time.
- Plasma Plasma-Lyte A Effect of prefreezing treatment of highly active NK cells. Treatment with KBM501 with 4-PBA added before freezing improved Viability during thawing. Recovery rate of highly active NK cells frozen and thawed after 2 hours pretreatment.
- Highly active NK cells after washing and freezing with KBM501 medium or PBS are thawed at room temperature, allowed to stand at room temperature for each hour without dilution operation, and then diluted 10-fold with KBM501 medium or Plasma-Lyte A, 7- Staining with AAD was performed and analyzed with FlowJo software (left).
- Highly active NK cells after washing and freezing with KBM501 medium or PBS are thawed at 37 ° C, allowed to stand at room temperature for each hour without dilution operation, and then diluted 10-fold with KBM501 medium or Plasma-Lyte A, 7 -Stained with AAD and analyzed with FlowJo software (right).
- Viability transition Highly active NK cells after washing and freezing with KBM501 medium or PBS are thawed at 37 ° C, diluted 10-fold with KBM501 medium or Plasma-Lyte A, allowed to stand at room temperature for 0 to 6 hours, and then with 7-AAD. Staining was performed and analyzed with FlowJo software. Viability transition. Effects of dilution with Plasma-Lyte A serially diluted with sterile distilled water and standing at 37 ° C. The cells after each treatment were stained with 7-AAD and analyzed with FlowJo software (same in the figure below). Continuation of Figure 12-1 Viability transition.
- mM is used in the same meaning as mmol / L unless otherwise specified.
- a numerical range is represented by x to y, the range includes the values x and y at both ends.
- the present invention relates to a method for cryopreserving cells having high cytotoxic activity.
- Applicable cells The present invention can be applied to various cells.
- One of the cells to which the present invention can be preferably applied is a cell that has undergone an activation operation by using some cytokine in vitro, and such cells include NK cells having high cytotoxic activity (highly active NK cells) and the like. Is included.
- the activation procedure typically relies on incubating cells with medium containing interleukin (IL) -2.
- IL interleukin
- NK cells are large granular lymphocytes that do not express the T cell receptor (TCR), the T cell universal marker CD3, and the membrane immunoglobulin B cell receptor, usually humans. Is CD16 positive and CD56 positive. Those skilled in the art can easily determine whether or not they are NK cells based on the expression pattern of cell surface markers and the like. NK cells have cytotoxic activity, and the presence or absence and degree of this cytotoxic activity can be measured by various known methods. NK cells can include peripheral blood NK cells, cord blood NK cells, primary NK cells, cultured NK cells, and highly active NK cells.
- Raw materials such as highly active NK cells to which the present invention can be preferably applied may be peripheral blood, cord blood, bone marrow and / or lymph nodes, and blood collected by the apheresis method (apheresis blood).
- the raw materials are hematopoietic stem cells derived from any stem cell selected from the group consisting of embryonic stem cells, adult stem cells and artificial pluripotent stem (iPS) cells, cord blood-derived hematopoietic stem cells, peripheral blood-derived hematopoietic stem cells, and the like.
- the donor of the raw material may be the patient who receives immunotherapy with highly active NK cells or the like, a close relative of the patient, or a healthy person who has no blood relationship with the patient. There may be multiple donors.
- the medium used for culturing highly active NK cells is KBM501 medium (Kojin Bio Co., Ltd. containing 1,750 JRU / mL of IL-2) and Cosmedium 008 (Cosmo Bio. IL-2 of 1,750 JRU / mL).
- Preferred examples are KBM501 medium, FKCM101 or Cosmedium 008.
- cells when cells are cultured, unless otherwise specified, for any purpose selected from the group consisting of cell survival maintenance, cell amplification, and cell activation. It means to maintain cells in a medium or a similar solution for a certain period of time. When the treatment is performed at a specific temperature for a certain period of time, it is sometimes called incubation.
- IL-2 may be added to the medium at a concentration that can achieve the object of the present invention.
- concentration of IL-2 may range from 2500 IU / mL to 2813 IU / mL.
- IL-2 preferably has a human amino acid sequence and is preferably produced by recombinant DNA technology for safety reasons.
- IL-2 concentrations may be expressed in national standard units (JRU) and international units (IU). Since 1 IU is about 0.622 JRU, 1750 JRU / mL of existing medium corresponds to about 2813 IU / mL.
- IL-12 When any one selected from the group consisting of IL-12, IL-15, and IL-18 is added at the same time as or in place of IL-2 described above at a concentration that can achieve the object of the present invention.
- Non-Patent Document 2 Leong JW et al. Biol Blood Marrow Transplant 20 (2014) 463-473. Each concentration may range from 1 pg / mL to 1 ⁇ g / mL, regardless of the presence or concentration of other cytokines.
- IL-2 preferably has a human amino acid sequence and is preferably produced by recombinant DNA technology for safety reasons.
- the subject's autologous serum, human ABO blood group available from BioWhittaker and others, and blood donated human serum albumin available from the Japanese Red Cross Society may be added to the medium.
- Autologous serum and human ABO blood group serum are preferably added at a concentration of 1 to 10%
- blood donated human serum albumin is preferably added at a concentration of 1 to 10%.
- Human platelet lysate (HPL) may be added with or in place of serum.
- HPL is commercially available, and the UltraGROTM series (AventaCell BioMedical) and others are on sale. When HPL is used, heparin sodium may be further added to the medium.
- the medium may contain appropriate proteins, cytokines, antibodies, compounds and other components, provided that the NK cell culture effect is not impaired.
- Cytokines include IL-2, IL-12, IL-15, and IL-18 mentioned above, as well as IL-3, IL-7, IL-21, stem cell factor (SCF), and / or FMS-like tyrosine kinases. May be 3 ligands (Flt3L). All of these preferably have a human amino acid sequence and are preferably produced by recombinant DNA technology for safety reasons.
- the medium is preferably a serum-free medium.
- the serum-free medium preferably contains serum albumin, transferrin, and insulin.
- Serum-free media for culturing lymphocytes have been developed and marketed, and they can be utilized in the present invention.
- One of the preferred examples of the serum-free medium is a basal medium supplemented with CTS Immuno Cell SR (Thermo Fisher Scientific), which is commercially available as a composition that supports the growth of human T cells.
- the medium may be replaced or replenished at any time after the start of culturing, provided that the desired culturing effect is obtained, but it is preferably every 3 to 5 days.
- Culture vessels used for culturing include, but are not limited to, commercially available dishes, flasks, plates, multi-well plates.
- the culturing conditions are not particularly limited as long as the culturing effect of NK cells is not impaired, but culturing conditions at 37 ° C., 5% CO 2 and a saturated steam atmosphere are common.
- the culturing period is not particularly limited as long as the desired culturing effect can be obtained.
- Highly active NK cells and the like to which the present invention can be preferably applied include the following [1], [2], [3] and [4].
- NK cells having the following characteristics (1) and (2): (1) CD16 positive, CD56 highly expressed, and CD57 negative. (2) NKG2C positive, NKG2A negative to low expression, and CD94 positive.
- the highly active NK cells of [1] may be highly expressed in CD16. Further, the highly active NK cells of [1] may further have the following characteristics regardless of whether or not they are highly expressed in CD16. (3)
- the cytotoxic activity is 50% or more when the NK cells are used as effector cells (E) and K562 cells are used as target cells (T) and co-cultured at a mixing ratio (E: T) of 1: 1.
- the highly active NK cells in [1] can also be expressed as: From healthy human-derived peripheral blood mononuclear cells, CD3 beads (eg, CliniMACS CD3, Miltenyi Biotec, Catalog No. 130-017-601), LD columns (eg, Miltenyi Biotec, Catalog No. 130-042-901) and Cell populations from which CD3-positive cells have been removed using a separation buffer (eg, 0.5% human AB serum (deactivated), PBS containing 2 mM EDTA) are cultivated in a suitable medium (eg, 5% human AB serum).
- a separation buffer eg, 0.5% human AB serum (deactivated)
- PBS containing 2 mM EDTA eg, 5% human AB serum
- NK cells obtained by culturing in Cosmedium 008) supplemented with (inactivated) for 14 days and having the following characteristics (1) and (3): (1) CD16 positive, CD56 highly expressed, and CD57 negative. (3) The cytotoxic activity is 50% or more when the NK cells are used as effector cells (E) and K562 cells are used as target cells (T) and co-cultured at a mixing ratio (E: T) of 1: 1.
- Japanese Patent Application Laid-Open No. 2018-193303 can be referred to.
- the cells of [2] may be further highly expressive of CD11c.
- the cells in [2] can also be represented as: Cells that are CCR5 positive, CCR6 positive, CXCR3 positive, Integrin ⁇ 1 positive, Integrin ⁇ 3 positive and Integrin ⁇ 3 negative and CD3 negative.
- Cells that are CCR5 positive, CCR6 positive, CXCR3 positive, CD11a high expression and CD11c high expression and CD3 negative, high expression of substantially uncultured NK cells obtained from peripheral blood. Cells, as determined by comparison with expression in the population.
- the cells of [2] show extremely high cytotoxic activity against solid cancers that have formed tumor masses.
- Japanese Patent Application Laid-Open No. 2019-170176 can be referred to for details of the cell characteristics of [2] and a more specific production method.
- CD3 beads eg, CliniMACS CD3, Miltenyi Biotec, 130-017-601 ( 5 ⁇ L per 1x10 7 cells)
- frozen apheresis blood on mononuclear cells from fresh peripheral blood or from frozen apheresis blood.
- a separation buffer eg, 0.5% human.
- Add type AB serum inactivated at 56 ° C.
- an appropriate medium for example , 5x10 5 cells / mL when using peripheral blood and 1x10 6 cells / mL when using frozen aferesis blood
- an appropriate medium for example , 5x10 5 cells / mL when using peripheral blood and 1x10 6 cells / mL when using frozen aferesis blood
- 5% human AB serum inactivated at 56 ° C for 30 minutes
- 5% UltraGRO AventaCell, HPCPLCRL10
- the cells are suspended and cultured until the 14th day while changing the medium as appropriate.
- the present invention may be described by using highly active NK cells as an example, but those skilled in the art may use some other cytokine in vitro according to the description. It is also possible to understand the case of using cells that have undergone the activation operation by.
- the term “active or cytotoxic activity” with respect to highly active NK cells and the like refers to the lytic ability of a target cell (effector cell, E) to a target cell (T) unless otherwise specified.
- the cytotoxic activity can be expressed as a percentage (%) of the target cells that have died by the effector cells, and is calculated by the following formula.
- the mixing ratio of effector cells and target cells (E: T) and the co-culture time of effector cells and target cells are determined according to the degree of cytotoxic activity of effector cells. , It can be appropriately adjusted according to the type of cells used and the strength of activity.
- the target cells may be, but are not limited to, K562 cells, acute myelogenous leukemia cells, and chronic myelogenous leukemia cells. Effector cells and target cells, live cells and dead cells can be distinguished and quantified by reagents such as antibodies labeled with radioactive substances and fluorescent dyes.
- T 2: 1 for 1 to 3 hours, more specifically 2 hours.
- the activity is preferably 60% or more, more preferably 70% or more.
- highly active NK cells and the like to be frozen are recovered from the culture system prior to the freezing step described later. Recovery can be performed by centrifuging to separate the medium and cells. If necessary, EDTA at an appropriate concentration may be added to the culture system, and the adhered cells may be exfoliated from the surface of the culture vessel. Alternatively, the surface of the culture vessel after the medium may be washed with an appropriate solution to obtain the remaining cells. The resulting cells are washed with a suitable solution and suspended in a suitable solution, if necessary.
- a solution such as a medium, an isotonic solution, or a buffer solution can be used for exfoliation and washing of cells.
- media that can be used are KBM501 medium, Cosmedium 008, FKCM101, CellGro SCGM medium, X-VIVO15 medium, Gibco (registered trademark) CTS (registered trademark) AIM V (registered trademark) Medium, CTS OpTmizer T Cell Expansion Basal. Examples include Medium, IMDM, MEM, DMEM and RPMI-1640.
- the isotonic liquid is a liquid having an osmotic pressure substantially equal to the osmotic pressure (285 ⁇ 5 mOsm / L) of the body fluid (plasma), and in the present invention, it is a liquid having an osmotic pressure of 285 ⁇ 13 mOsm / L.
- the osmotic pressure of Plasma-Lyte A is 294 mOsm / L
- the osmotic pressure of PBS (-) is 280 ⁇ 4 mOsm / L (freezing point drop method).
- Examples of usable isotonic solutions include Plasma-Lyte A (Baxter), physiological saline, Ringer's solution (Lactated Ringer's solution, Ringer's acetate solution, Ringer's bicarbonate solution, etc.), and 5% aqueous glucose solution.
- Examples of buffers that can be used include Phosphate-buffered saline (PBS), Tris hydrochloride buffer, Tris acetate buffer, and HEPES buffer.
- the medium for culturing human lymphocytes may contain human serum albumin, human transferrin, recombinant human insulin, and recombinant human IL-2.
- Preferred examples of such media are KBM501 medium, FKCM101 or Cosmedium 008.
- KBM501 medium contains human serum albumin, human transferrin, recombinant human insulin, recombinant human IL-2, and no other proteins.
- the KBM501 medium also contains an antibiotic (kanamycin), LVDS 3 , L-Glutamine, and a pH regulator.
- PBS (-) typically contains sodium chloride 136.9 mM, potassium chloride 2.68 mM, disodium hydrogen phosphate 8.1 mM, and potassium hydrogen phosphate 1.47 mM.
- Pretreatment In the present invention, highly active NK cells or the like to be frozen may be pretreated prior to the freezing step described later. Pretreatment is the suspension of the recovered cells in a solution containing the additive. Pretreatment involves recovery with a solution containing additives.
- any one selected from the group consisting of bile acid and phenylbutyric acid can be used.
- bile acids are tauroursodeoxycholic acid (TUDCA), ursodeoxycholic acid (UDCA), kenodeoxycholic acid, cholic acid, hyodeoxycholic acid, deoxycholic acid, 7-oxolithocholic acid, lithocholic acid, iododeoxycholic acid. Acids, iocholic acid, taurokenodeoxycholic acid, taurodeoxycholic acid, glycoursodeoxycholic acid, taurocholic acid, glycocholic acid or its analogs and derivatives.
- TDCA tauroursodeoxycholic acid
- UDCA ursodeoxycholic acid
- kenodeoxycholic acid cholic acid
- hyodeoxycholic acid deoxycholic acid
- 7-oxolithocholic acid lithocholic acid
- phenylbutyric acid examples include 4-phenylbutyric acid (4-PBA), gluceryl (tri-4-PBA), phenylacetic acid, 2-POAA-OMe, 2-POAA-NO2, 2-NOAA or pharmaceutically acceptable thereof. , Salt, analog, derivative or prodrug.
- a particularly preferred example of the additive used in the pretreatment is one selected from the group consisting of TUDCA and 4-PBA.
- the concentration may be appropriate, but it is preferably 100 to 5000 ⁇ M, more preferably 200 to 2500 ⁇ M, and further preferably 400 to 1000 ⁇ M. Such a range is particularly suitable when using TUDCA.
- the concentration may be appropriate, but is preferably 1 to 1000 ⁇ M, more preferably 5 to 500 ⁇ M, and even more preferably 10 to 100 ⁇ M. Such a range is particularly suitable when using 4-PBA.
- DMSO dimethyl sulfoxide
- concentration can be adjusted as appropriate, but is preferably 0.5 to 15%, more preferably 1 to 12.5%, and even more preferably 2 to 10%.
- the solution for pretreatment can be a solution such as a medium, an isotonic solution, or a buffer solution, similar to the solution used for recovery.
- One of the preferred examples of the solution used in the pretreatment is a medium, more preferably a medium for culturing human lymphocytes, and even more preferably KBM501 medium, FKCM101 or Cosmedium 008.
- the medium used for pretreatment may also contain human serum albumin, human transferrin, recombinant human insulin, and recombinant human IL-2, antibiotics (kanamycin), LVDS 3 , L-Glutamine, pH. It may contain a regulator.
- the time for pretreatment is not particularly limited.
- the suspension may be allowed to stand for minutes to hours, for example 5 minutes to 4 hours, more preferably 30 minutes to 3 hours after suspending the cells for pretreatment.
- Standing may be performed at ambient temperature (eg 1-30 ° C, typically 15-25 ° C) or in a CO 2 incubator (eg 36-42 ° C, typically 37 ° C). ..
- the cell density at the time of pretreatment can be appropriately set, but it is preferable that the cell density is suitable for maintaining cells. Specifically, it is 1x10 5 to 1x10 7 cells / mL, preferably 2x10 5 to 5x10 6 cells / mL, and more preferably 5x10 5 to 2x10 6 cells / mL.
- pretreatment TUDCA the 400 ⁇ 1000 [mu] M or 4-PBA the KBM501 medium added 10 ⁇ 100 [mu] M, the FKCM101 or Cosmedium 008, as cell density is 5x10 5 ⁇ 2x10 6 cells / mL To suspend. At this time, it is advisable to incubate at 37 ° C. under 5% CO 2 for 30 minutes to 3 hours.
- pretreatment is not essential in the present invention, by pretreating highly active NK cells and the like with KBM501 medium supplemented with 4-PBA or TUDCA before freezing, the cells can be treated as compared with the case where no pretreatment is performed.
- the survival rate (which can also be called the recovery rate) when thawed can be improved.
- the recovered, preferably pretreated cells are frozen by conventional procedures. Specifically, if necessary, the number of cells and the viability are confirmed, and after centrifugation to remove the supernatant, the cells are suspended in a cryopreservation solution so as to have an appropriate cell density. After dispensing the cell suspension into a container for cryopreservation, freeze it in a deep freezer at -80 ° C and store it. If necessary, freeze in a liquid nitrogen tank.
- the cryopreservation solution that can be used in the present invention may contain a sodium salt, a potassium salt, a sugar, a hydrogen carbonate, a carbonate, and a frost damage protective agent.
- the sodium salt that can be used is not particularly limited as long as it produces sodium ions when dissolved in a solvent, and may be an oxo acid salt, a halide, an oxide, a hydroxide, an inorganic salt, an organic acid salt, or the like. ..
- the sodium salt may be used alone or in combination of two or more.
- sodium chloride is preferably used as one type, and sodium chloride and sodium citrate are preferably used as a plurality of types.
- the sodium salt content is not particularly limited, but the final concentration of all sodium ions contained in the cryopreservation solution is preferably 0.01 to 5000 mM, more preferably 0.1 to 1000 mM, and even more preferably 1 to 300 mM.
- the potassium salt that can be used is not particularly limited as long as it produces potassium ions when dissolved in a solvent, and may be an oxo acid salt, a halide, an oxide, a hydroxide, an inorganic salt, an organic acid salt, or the like. ..
- the potassium salt may be used alone or in combination of two or more. Potassium chloride is preferably used in the present invention.
- the potassium salt content is not particularly limited, but the final concentration of total potassium ions contained in the cryopreservation solution is preferably 0.01 to 5000 mM, more preferably 0.1 to 1000 mM, and even more preferably 1 to 100 mM.
- the usable hydrogen carbonate is not particularly limited as long as it produces hydrogen carbonate ions when dissolved in a solvent, and salts with various cations can be used.
- ammonium hydrogen carbonate, potassium hydrogen carbonate, calcium hydrogen carbonate, sodium hydrogen carbonate, magnesium hydrogen carbonate and the like can be mentioned.
- the carbonates that can be used are not particularly limited as long as they generate carbonate ions when dissolved in a solvent, and salts with various cations can be used.
- ammonium carbonate, potassium carbonate, calcium carbonate, sodium carbonate, barium carbonate, magnesium carbonate and the like can be mentioned.
- These hydrogen carbonates and / or carbonates may be used alone or in combination of two or more.
- Sodium hydrogen carbonate is preferably used in the present invention.
- the content of bicarbonate and / or carbonate is not particularly limited, but the total final concentration of hydrogen carbonate ion and carbonate ion contained in the cryopreservation solution is preferably 0.01 to 1000 mM, more preferably 0.1 to 500 mM. It is more preferably 1 to 100 mM.
- the concentration ratio of sodium ions to potassium ions (sodium ion / potassium ion) in the cryopreservation solution is preferably 1/1000 to 1000/1, more preferably 1/100 to 100/1, and even more preferably 1/10 to 100. It is / 1, more preferably 1/1 to 100/1, and even more preferably 10/1 to 50/1.
- Usable sugars are monosaccharides, oligosaccharides or sugar alcohols, for example glucose, galactose, fructose, mannose, xylose, arabinose as monosaccharides, trehalose, sucrose, maltose, lactose, cellobiose, sugars as oligosaccharides.
- the alcohol include xylitol, sorbitol and the like.
- These saccharides may be used alone or in combination of two or more, but in the present invention, they are preferably at least one saccharide selected from the group consisting of glucose, galactose, fructose, mannose, xylose, and arabinose. , More preferably glucose.
- the content of saccharides in the cryopreservation solution is preferably 0.01 to 100 g / L, more preferably 0.1 to 100 g / L, and even more preferably 0.25 to 50 g / L.
- frost damage protective agents examples include dimethyl sulfoxide (DMSO), hydroxyethyl starch (HES), ethylene glycol, glycerol and the like.
- the frost damage protective agent may be used alone or in combination of two or more.
- any one selected from the group consisting of DMSO and hydroxyethyl starch is preferably used.
- the total content is preferably within the above range, and the respective concentrations are such that the DMSO concentration is preferably 0.01 to 50%, more preferably 1 to 1. It is 30%, more preferably 2 to 15%, and the hydroxyethyl starch concentration is preferably 0.01 to 50%, more preferably 1 to 30%, still more preferably 2 to 15%.
- a component selected from the group consisting of protein, magnesium salt and calcium salt is further contained.
- proteins that can be used include serum albumin and serum globulin.
- serum albumin examples include human serum albumin and bovine serum albumin.
- human serum albumin is suitable.
- the protein content is preferably 0.01 to 50%, more preferably 1 to 30%, still more preferably 2 to 15% in the cryopreservation solution.
- the magnesium salt that can be used is not particularly limited as long as it produces magnesium ions when dissolved in a solvent, and an oxo acid salt, a halide, an oxide, a hydroxide, an inorganic salt, an organic acid salt, or the like may be used. Can be done.
- the magnesium salt may be used alone or in combination of two or more.
- Magnesium chloride is preferably used in the present invention.
- the magnesium salt content is not particularly limited, but the final concentration of all magnesium ions contained in the cryopreservation solution is preferably 0.01 to 10 mM, more preferably 0.1 to 5 mM.
- the calcium salt that can be used is not particularly limited as long as it produces calcium ions when dissolved in a solvent, and an oxo acid salt, a halide, an oxide, a hydroxide, an inorganic salt, an organic acid salt, or the like is used. Can be done.
- the calcium salt may be used alone or in combination of two or more. Calcium chloride is preferably used in the present invention.
- the calcium salt content is not particularly limited, but the final concentration of all calcium ions contained in the cryopreservation solution is preferably 0.01 to 10 mM, more preferably 0.1 to 5 mM.
- the cryopreservation solution may further contain substances that are not damaging to cells, such as vitamins and amino acids.
- the cryopreservation solution may contain phosphate ions from the viewpoint of exerting pH adjustment and buffering action.
- the osmotic pressure of the cryopreservation solution is preferably in the range that does not damage the cells during freezing, and from the viewpoint of increasing the permeability of the components into the cells during freezing and inhibiting ice crystal formation, for example, 500 to 8000 mOsm. It may be / L, 1000 to 7500 mOsm / L, 1500 to 7000 mOsm / L, or 1800 to 5000 mOsm / L.
- the pH of the cryopreservation solution is preferably in the range that does not damage the cells, for example, 3.0 to 10.0, and more preferably 4.5 to 9.0.
- cryopreservation liquid may be used.
- products that can be used include the cell / tissue cryopreservation solution cell bunker series (STEM-CELLBANKER (registered trademark)), and more specifically, STEM-CELLBANKER (ZENOAQ, CB045).
- the cells at the time of freezing are in the logarithmic growth phase.
- the cell density at the time of freezing can be appropriately adjusted, but specifically, it is 1x10 6 to 2x10 8 cells / mL, preferably 2x10 6 to 1x10 8 cells / mL, and more preferably 1x10 7 to. 5x10 7 cells / mL.
- cells are stored at 4x10 7 cells / mL in a 5 mL volume container. Freezing of highly active NK cells The ability to freeze at high density when shipping contributes to making the product more compact and reducing transportation costs.
- cryopreserved cells can be thawed by various procedures.
- a container for cryopreservation containing cells can be quickly thawed in a warm bath at 37 ° C while shaking as necessary.
- it can be naturally thawed by leaving it at room temperature without actively heating it after taking it out of the freezer.
- the thawed cells are mixed with the appropriate thawing solvent I. If necessary, the supernatant can be removed by centrifugation and suspended in an appropriate amount of thawing solvent II for culturing or activation treatment.
- thawing solvent I the solution used for thawing the frozen cells suspended in the cryopreservation solution and diluting them together with the cryopreservation solution.
- thawing solvent I Various solvents can be used as the thawing solvent I for the cells collected according to the present invention, pretreated as necessary, and cryopreserved.
- the thawing solvent I may contain a sodium salt, a potassium salt, a gluconate salt, and an acetate salt. It may also contain magnesium salts.
- the sodium salt that can be used as the thawing solvent I can be an oxo acid salt, a halide, an oxide, a hydroxide, an inorganic salt, an organic acid salt, or the like.
- the sodium salt may be used alone or in combination of two or more.
- the thawing solvent I preferably contains any one selected from the group consisting of sodium chloride, sodium gluconate, and sodium acetate, and more preferably contains sodium chloride, sodium gluconate, and sodium acetate.
- the content of the sodium salt of the solvent I at the time of thawing is preferably 14.0 to 200 mM, more preferably 28.0 to 182 mM, and further preferably 70.0 to 168 mM as the final concentration of all sodium ions. Alternatively, it is preferable to contain 9.00 to 108 mM as sodium chloride, 2.30 to 27.7 mM as sodium gluconate, and 2.70 to 32.5 mM as sodium acetate.
- the potassium salt that can be used in the thawing solvent I can be an oxo acid salt, a halide, an oxide, a hydroxide, an inorganic salt, an organic acid salt, or the like.
- the potassium salt may be used alone or in combination of two or more.
- the thawing solvent I preferably contains any one selected from the group consisting of potassium chloride, potassium gluconate, and potassium acetate, and more preferably contains potassium chloride.
- the content of the potassium salt of the solvent I at the time of thawing is preferably 0.50 to 8.0 mM, more preferably 1.0 to 7.0 mM, and further preferably 2.5 to 6.0 mM as the final concentration of total potassium ions.
- potassium chloride preferably contains 0.496 to 5.96 mM.
- the gluconate salt that can be used as the solvent I at the time of thawing is not particularly limited as long as it produces gluconate ions when dissolved in the solvent, and salts with various cations can be used.
- the thawing solvent I preferably contains sodium gluconate.
- the content of gluconate in solvent I at the time of thawing is preferably 2.3 to 32.3 mM, more preferably 4.6 to 29.9 mM, and further preferably 12.5 to 27.7 mM as the final concentration of total gluconate ions. ..
- the acetate salt that can be used in the solvent I at the time of thawing is not particularly limited as long as it produces acetate ions when dissolved in the solvent, and salts with various cations can be used.
- salts with various cations can be used.
- sodium acetate, potassium acetate and the like can be mentioned.
- the thawing solvent I preferably contains sodium acetate.
- the content of the acetate of Solvent I at the time of thawing is preferably 2.7 to 37.8 mM, more preferably 5.4 to 35.1 mM, and further preferably 13.5 to 32.5 mM as the final concentration of total acetate ions.
- a commercially available isotonic solution may be used as the thawing solvent I.
- examples of products that can be used include Plasma-Lyte A, and a solution obtained by diluting it with water. Specifically, it is a liquid containing the following. ⁇ Sodium chloride 9.00-108mM ⁇ Sodium gluconate 2.30-27.7 mM ⁇ Sodium acetate 2.70-32.5 mM ⁇ Potassium chloride 0.496-5.96 mM ⁇ Magnesium chloride 0.148-1.78mM
- the thawing solvent I may contain only sodium salts.
- the sodium salt that can be used in the thawing solvent I may be an oxo acid salt, a halide, an oxide, a hydroxide, an inorganic salt, an organic acid salt, or the like.
- the sodium salt may be used alone or in combination of two or more.
- the thawing solvent I preferably contains only sodium chloride.
- the content of the sodium salt of the solvent I at the time of thawing is preferably 15.4 to 216 mM, more preferably 30.8 to 200 mM, and further preferably 70.0 to 185 mM as the final concentration of all sodium ions.
- physiological saline or a solution obtained by diluting it with water may be used.
- the cells suspended in the solvent I at the time of thawing together with the solution for cryopreservation can be used as they are for administration.
- the mixed solution becomes isotonic after mixing the solution for cryopreservation and the solvent I at the time of thawing (having an osmotic pressure almost equal to that of the body fluid, specifically 285 ⁇ ). 13mOsm / L) is preferable.
- the liquid for cryopreservation is a hypertonic liquid (for example, 1500 to 7000 mOsm / L) in a preferred embodiment, the solvent I at the time of thawing may be a liquid having a low osmotic pressure.
- a person skilled in the art can appropriately determine the component concentration of the solvent I during thawing in consideration of the dilution ratio of the solution for cryopreservation with the solvent I during thawing.
- the solvent I at the time of thawing is specifically a liquid containing the following. ⁇ Sodium chloride 85.5-94.5 mM ⁇ Sodium gluconate 21.8-24.2 mM ⁇ Sodium acetate 25.6-28.5 mM ⁇ Potassium chloride 4.71-5.21 mM ⁇ Magnesium chloride 1.40 ⁇ 1.55mM Alternatively, the thawing solvent I is specifically a liquid containing the following. ⁇ Sodium chloride 146.3 to 161.7 mM
- the solvent I at the time of thawing does not contain calcium ions at a concentration of 0.423 mM or more. Further, in any composition, it is preferable that the solvent I at the time of thawing does not contain glucose at a concentration of 5.55 mM or more. Further, in any composition, it is preferable that the solvent I at the time of thawing does not contain lactate at a concentration of 27.7 mM or more. This is because the viability or cytotoxic activity of thawed cells may decrease. In this sense, RPMI medium, Hanks'Balanced Salt Solution (HBSS) (+), and Ringer's lactate solution may not be suitable for use as solvent I during thawing.
- HBSS Hanks'Balanced Salt Solution
- the solvent I at the time of thawing preferably contains no serum at a concentration of 40% or more, and more preferably does not contain any serum. This is because the inclusion of serum may reduce the viability of cells.
- the cell density when suspended in the solvent I at the time of thawing can be appropriately set, but it is preferable that the cell density is suitable for maintaining the cells or is suitable for administration. Specifically, it is 1x10 5 to 1x10 7 cells / mL, preferably 2x10 5 to 5x10 6 cells / mL, and more preferably 5x10 5 to 2x10 6 cells / mL.
- Cells can be maintained for a relatively long time in solvent I upon thawing.
- the suspension may be allowed to stand for several minutes to several hours, for example, 5 minutes to 6 hours, more preferably 30 minutes to 4 hours.
- Standing may be performed at ambient temperature (eg 1-30 ° C, typically 15-25 ° C) or in a CO 2 incubator (eg 36-42 ° C, typically 37 ° C). ..
- solvent II during thawing
- the cells after thawing the frozen cells with the thawing solvent I, the cells can be further cultured or activated using the thawing solvent II.
- the solution used for recovering the cells suspended in the thawing solvent I and resuspending them for culturing or activation is referred to as thawing solvent II.
- thawing solvent II various solvents can be used depending on the purpose.
- the present invention provides a pharmaceutical composition comprising highly active NK cells, etc., which have been recovered by an appropriate method, pretreated as necessary, and cryopreserved.
- the pharmaceutical composition provided by the present invention can be applied to the treatment and / or prevention of various diseases sensitive to highly active NK cells and the like.
- diseases are cancer or infectious diseases, specifically skin cancer, oral cancer, bile sac cancer, bile duct cancer, lung cancer, liver cancer, stomach cancer, colon cancer, It includes, but is not limited to, pancreatic cancer, kidney cancer, ovarian cancer, bladder cancer, prostate cancer, neuroblastoma, leukemia, and infections caused by viruses, bacteria, and the like.
- the present inventors have confirmed the effect on colorectal cancer model animals that die within 30 days without treatment using cells frozen and thawed by the method of the present application.
- the cell therapy with the pharmaceutical composition of the present invention may be carried out alone or in combination with surgical therapy, chemotherapy, radiotherapy, antibody drug and the like.
- Constituent cells Highly active NK cells, etc. Content: 6 x 10 6 to 4.8 x 10 9 cells / 60 kg
- the shelf life after thawing is 6 hours, preferably 4 hours when stored at room temperature.
- KBM501 medium so that the final volume on day 9 of culture is 6 mL per well for a 6-well plate, 50 mL per flask for a T-75 flask, and 500 mL per bag for a bag. It was added and incubated until day 14.
- cells obtained from PBMCs through this culture step will be referred to as "Highly activated NK cell-like CD3-negative cells” or simply “highly activated NK cells”. ..
- Recovery method 2 Method of the present application The culture solution was recovered on the 14th day of culture, 1 mM EDTA was added to the culture vessel to exfoliate the adhered cells, and the culture vessel after collecting the detached cells was washed with KBM501 medium. All cell recovery solutions were centrifuged, washed with KBM501 medium, and resuspended.
- Highly active NK cells PBMC, K562 (human chronic myelogenous leukemia cell line), THP-1 (human acute monocytic leukemia cell line) obtained by the procedure described in the method for culturing and recovering highly active NK cells 1.
- PBMC, K562 human chronic myelogenous leukemia cell line
- THP-1 human acute monocytic leukemia cell line
- NK cells have a high iron content. From the morphological observation results and the time to death, it was assumed that the Viability of highly active NK cells significantly decreased by freezing and thawing in five morphologies: Ferroptosis (oxidative stress), Apoptosis, Autophagy, Necrosis and Necroptosis. .. Inhibitors for each form are shown below.
- NK cells The number of viable cells of highly active NK cells obtained by the procedure described in the method for culturing and recovering highly active NK cells was counted, and 1x10 7 cells were suspended in 1 mL of STEM-CELLBANKER (ZENOAQ, CB045). Frozen at -80 ° C. NK cells frozen for 48 hours or more were thawed in a water bath at 37 ° C., diluted 10-fold with the following solvent, allowed to stand at each temperature and time, and then observed and photographed with an optical microscope. ..
- Fig. 1-2 The results are shown in Fig. 1-2. It was confirmed that the Viability of highly active NK cells was significantly reduced by freezing and thawing. This was also not improved by the addition of Methylprednisolone, Dexamethasone, or Z-Vad after freeze-thaw.
- the highly active NK cells obtained by the procedure described in the method for culturing and recovering highly active NK cells 1 were recovered and then frozen and thawed by the method as described.
- Example 1 (1-1) The number of viable cells of highly active NK cells obtained by the procedure described in the method of culturing and recovering highly active NK cells from each of two healthy volunteers was counted, and 1x10 7 cells and 8x10, respectively. 6 cells were suspended in 1 mL of STEM-CELLBANKER (ZENOAQ, CB045) and frozen at -80 ° C. NK cells frozen for 48 hours or more were thawed in a water bath at 37 ° C., and immediately after thawing, 1x10 5 cells were separated into 96-well plates (IWAKI).
- STEM-CELLBANKER ZENOAQ, CB0405
- NK cells frozen for 48 hours or more were thawed in a water bath at 37 ° C., and immediately after thawing, 1x10 5 cells were separated into 96-well plates (IWAKI).
- KBM501 medium 3500 units / mL IL-2 (Seroiku® injection 40, Takeda Yakuhin Kogyo), lactolinger containing 139.9 mM maltose (Fuso Yakuhin Kogyo), Plasma containing 3500 units / mL IL-2.
- KBM501 medium 3500 units / mL IL-2 (Seroiku® injection 40, Takeda Yakuhin Kogyo), lactolinger containing 139.9 mM maltose (Fuso Yakuhin Kogyo), Plasma containing 3500 units / mL IL-2.
- KBM501 medium containing Lyte A (Baxter)
- 5.02 mg / mL sodium gluconate Nacalai, 16720-22
- Example 2 The viable cells of highly active NK cells obtained by the procedure described in the method for culturing and recovering highly active NK cells are counted, and 5x10 6 cells and 1x10 7 cells are suspended in 1 mL of STEM-CELL BANKER at -80 ° C. Frozen. NK cells frozen for 48 hours or more were thawed in a water bath at 37 ° C., and immediately after thawing, 1x10 5 cells were separated into 96-well plates.
- Example 3 The number of viable cells of highly active NK cells obtained by the procedure described in the method for culturing and recovering highly active NK cells was counted, and 1x10 7 cells were suspended in 1 mL of STEM-CELL BANKER and frozen at -80 ° C. After thawing NK cells frozen for 48 hours or more in a water bath at 37 ° C, Plasma-Lyte A (solvent (1)) containing 3500 units / mL IL-2 (Immnes, Shionogi Pharmaceutical Co., Ltd.), or Diluted with KBM501 medium (solvent (2)), the number of viable cells, viable cell rate, and cytotoxic activity rate (% Lysis) after dilution were calculated for each of the following groups.
- ⁇ 4> Dilute 10-fold with solvent (1), leave at 37 ° C for 1 hour, add lactoline gel containing an equal amount of IL-2, and incubate at 37 ° C overnight.
- ⁇ 5> Dilute 10-fold with solvent (1) and leave at 37 ° C for 3 hours.
- ⁇ 6> Dilute 10-fold with solvent (2) and leave at 37 ° C for 3 hours.
- ⁇ 7> Dilute 10-fold with solvent (2) and leave overnight at 37 ° C.
- cytotoxic activity rate For the measurement of cytotoxic activity, a group in which NK cells and K562 cells were reacted, a group in which only K562 cells were used as a negative control, and a group in which K562 cells were fixed with 10% formalin were prepared as a positive control.
- ⁇ NK cells After incubating for the time described in each group, cells were harvested and adjusted to a concentration of 2x10 6 cells / mL with 10% FBS / RPMI 1640.
- K562 cells K562 cells in which K562 cells (human chronic myelogenous leukemia cell line) were suspended in RPMI1640 medium containing no serum component were stained with PKH26 Red Fluorescent Cell Linker Kit (Sigma, PKH26GL-1KT), and finally 10 It was prepared to be 2x10 6 cells / mL with% FBS / RPMI1640.
- Fig. 3 For frozen and thawed highly active NK cells, the number of viable cells and Viability were correlated. In addition, the number of viable cells or Viability and cytotoxic activity tended to be inversely correlated. Furthermore, when the treatment solution for frozen and thawed cells was switched from Plasma-Lyte A to another solution, Viability decreased.
- Example 4 The number of viable cells of highly active NK cells obtained by the procedure described in the method for culturing and recovering highly active NK cells is counted and suspended in the following 6 kinds of solvents so as to be 1x10 6 cells / mL. , Pre-freezing treatment was performed by seeding on a low-adsorption 6-well plate (IWAKI, 4810-800SP).
- the pretreatment solvent includes (1) KBM501 medium containing 10 ⁇ M 4-phenylbutyric acid (4-PBA, Tokyo Kasei Kogyo Co., Ltd., P0643), (2) KBM501 medium containing 100 ⁇ M 4-phenylbutyric acid, and (3) Plasma- Lyte A, (4) Plasma-Lyte A containing 3000 units / mL IL-2 (Immnes, Shionogi Co., Ltd.), (5) Plasma-Lyte A containing 10 ⁇ M Salubrinal (TOCRIS, 2347), (6) 23 mM Using PBS containing sodium gluconate, cells suspended in each solvent were placed at 37 ° C for groups (1) and (2) under 5% CO 2 , and for 2 hours at room temperature for groups (3) to (6).
- NK cells were suspended in STEM-CELLBANKER so as to have 1x10 7 cells / mL based on the number of cells at the time of treatment, and cryopreserved at -80 ° C.
- Pretreated NK cells frozen for 48 hours or more were thawed in a water bath at 37 ° C. and diluted as follows. Dilution and incubation after thawing were all carried out in a low adsorption 6-well plate.
- KBM501 medium containing 10 ⁇ M 4-phenylbutyric acid Dilute 11-fold each in Plasma-Lyte A containing 1000 units / mL IL-2 or Plasma-Lyte A containing 1000 units / mL IL-2 and 100 ⁇ M 4-PBS, incubate at room temperature for 1 hour, and then in KBM501 medium 5 It was diluted 2-fold.
- KBM501 medium containing 100 ⁇ M 4-phenylbutyric acid >> It was diluted 11-fold with Plasma-Lyte A, incubated at room temperature for 1 hour, and then diluted 5-fold with RPMI medium * 6 or RPMI medium containing 2400 units / mL IL-2.
- Plasma-Lyte A Dilute 11-fold each in Plasma-Lyte A containing 1000 units / mL IL-2 or Plasma-Lyte A containing 1000 units / mL IL-2 and 100 ⁇ M 4-PBA, incubate at room temperature for 1 hour, and then in KBM501 medium 5 It was diluted 2-fold.
- Plasma-Lyte A containing 10 ⁇ M Salubrinal ⁇ Dilute 11-fold each in Plasma-Lyte A containing 1000 units / mL IL-2 and Plasma-Lyte A containing 1000 units / mL IL-2 and 100 ⁇ M 4-PBA, incubate at room temperature for 1 hour, and then in KBM501 medium 5 It was diluted 2-fold.
- the cells of each group diluted in the medium were incubated overnight at 37 ° C. under 5% CO 2 , and then the number of viable cells was counted.
- the experimental conditions are summarized below.
- Example 5 The number of viable cells of highly active NK cells obtained by the procedures described in the culture method, recovery method 1 and recovery method 2 of highly active NK cells was counted and suspended in various solvents so as to be 1x10 6 cells / mL. Pre-freezing treatment was performed by seeding in a low-adsorption 6-well plate. The NK cells obtained by the recovery method 1 were suspended in PBS and incubated at room temperature for 1 hour.
- the NK cells obtained by the recovery method 2 are (1) KBM501 medium, (2) KBM501 medium containing 30 ⁇ M 4-phenylbutyric acid, and (3) KBM501 containing 30 ⁇ M Tauroursodeoxycholic Acid Dihydrate (TUDCA, Tokyo Kasei Kogyo Co., Ltd., T1567). Cells suspended in medium, (4) KBM501 medium containing 30 ⁇ M 4-phenylbutyric acid and 30 ⁇ M TUDCA were incubated at 37 ° C. under 5% CO 2 for 2 hours.
- TDCA Tauroursodeoxycholic Acid Dihydrate
- the cells were suspended in STEM-CELLBANKER so as to have 1x10 7 cells / mL based on the number of cells at the time of treatment, and cryopreserved at -80 ° C.
- Pretreated highly active NK cells frozen for 48 hours or longer were thawed in a water bath at 37 ° C., diluted 11-fold with Plasma-Lyte A in each group, and incubated at room temperature for 1 hour. After 1 hour, the cells were gently suspended and the number of viable cells was counted. Further, the cells were diluted 5-fold in KBM501 medium and incubated at 37 ° C. under 5% CO 2 for 2 hours, and then the number of viable cells was counted and calculated as the recovery rate with respect to the number of cells at the time of freezing.
- Example 6 Count the number of viable cells of highly active NK cells obtained by the procedure described in the method for culturing and recovering highly active NK cells, and use only KBM501 medium or TUDCA (10 ⁇ M, 30 ⁇ M) so as to be 1x10 6 cells / mL. , 90 ⁇ M, 270 ⁇ M, 810 ⁇ M) were suspended in KBM501 medium, seeded on a low-adsorption 6-well plate, incubated at 37 ° C. under 5% CO 2 for 2 hours, and pre-frozen treatment was performed.
- the cells were suspended in STEM-CELLBANKER so as to have 1x10 7 cells / mL based on the number of cells at the time of treatment, and cryopreserved at -80 ° C.
- Pretreated NK cells frozen for 48 hours or longer were thawed in a water bath at 37 ° C., 10-fold amount of Plasma-Lyte A was added to each group, and the cells were incubated at room temperature for up to 3 hours. After 1 hour and 3 hours, the cells were loosely suspended and the number of viable cells was counted. After 1 hour, the cells were diluted 5-fold in KBM501 medium and incubated at 37 ° C. under 5% CO 2 for 2 hours, and the number of viable cells was counted. It was calculated from the number of viable cells at each point after thawing as the recovery rate with respect to the number of cells at the time of freezing. In addition, the cytotoxic activity of highly active NK cells was measured at each time point.
- cytotoxic activity rate For the measurement of cytotoxic activity, a group in which NK cells and K562 cells were reacted, a group in which only K562 cells were used as a negative control, and a group in which K562 cells were fixed with 10% formalin were prepared as a positive control.
- ⁇ NK cells The cells thawed and diluted by the method described were collected in the required amount based on the number of viable cells at the time of freezing, and then adjusted to a concentration of 2x10 6 cells / mL with 10% FBS / RPMI1640.
- K562 cells were suspended in serum-free RPMI1640 medium, stained with PKH26 Red Fluorescent Cell Linker Kit, and then prepared to 2x10 6 cells / mL with 10% FBS / RPMI1640.
- NK cells and K562 cells were added to a 96-well plate (IWAKI, 4870-800SP) so as to have a cell ratio of 2: 1 and mixed, and reacted at 37 ° C. under 5% CO 2 for 2 hours. After the reaction, the mixture was centrifuged (500 x g, 5 minutes), the supernatant was removed, a 7-AAD solution diluted with PBS was added and suspended, and the mixture was incubated at room temperature for 20 minutes. Measurements were performed using a flow cytometer and analyzed with FlowJo software to calculate the cytotoxic activity rate (% Lysis).
- the table below shows the recovery rate obtained together with the pretreatment conditions and thawing conditions.
- Pretreatment of highly active NK cells with KBM501 medium supplemented with TUDCA at various concentrations improved the recovery rate after thawing.
- Example 7 The number of viable cells of highly active NK cells obtained by the procedure described in the method for culturing and recovering highly active NK cells is counted so that the number of viable cells is 1x10 6 cells / mL.
- KBM501 medium only, 266 ⁇ M, 810 ⁇ M, 2400 ⁇ M TUDCA Suspended in KBM501 medium containing KBM501 medium, 2.4% DMSO (Nakalitesk, 13445-74), seeded in low-adsorption 6-well plates, incubated for 2 hours under 37 ° C., 5% CO 2 for prefreezing. went.
- the cells were suspended in STEM-CELLBANKER so as to have 1x10 7 cells / mL based on the number of cells at the time of treatment, and cryopreserved at -80 ° C.
- Pretreated NK cells frozen for 48 hours or longer were thawed in a water bath at 37 ° C., diluted 11-fold with Plasma-Lyte A or Plasma-Lyte A containing 3000 units / mL IL-2 in each group at room temperature. Incubated for up to 3 hours. After 1 hour and 3 hours, the cells were loosely suspended and the number of viable cells was counted. After 1 hour, the cells were diluted 5-fold in KBM501 medium and incubated at 37 ° C. under 5% CO 2 for 2 hours, and the number of viable cells was counted. It was calculated from the number of viable cells at each point after thawing as the recovery rate with respect to the number of cells at the time of freezing.
- cytotoxic activity of highly active NK cells against K562 cells was measured at each time point of thawing and dilution by the method described in Example 6.
- highly active NK cells 1 hour and 3 hours after thawing were evaluated using a solid tumor model (3D killing assay).
- highly active NK cells were prepared in KBM501 medium so as to be 1x10 6 cells / mL based on the number of cells at the time of freezing. 50 ⁇ L of prepared NK cells were added to one SKOV3 sphere seeded in advance in a 384-well plate, and the cells were reacted at 37 ° C. under 5% CO 2 for 4 days. Then, the cells were detached and collected by Accutase, and expanded and cultured in RPMI medium on a 24-well plate.
- ⁇ SKOV3 sphere ⁇ SKOV3 cells (human ovarian cancer cell line) were prepared so as to 3x10 4 cells / mL in 10% FBS / RPMI1640, were seeded 3x10 3/100 [mu] L per well of 96-well plates.
- a sphere was prepared by culturing at 37 ° C. under 5% CO 2 for 3 days.
- the table below shows the recovery rate obtained together with the pretreatment conditions and thawing conditions.
- Pretreatment of highly active NK cells with KBM501 medium supplemented with TUDCA at various concentrations improved recovery after thawing.
- Fig. 7-1 The measurement results of cytotoxic activity are shown in Fig. 7-1, and the results of evaluation using a solid tumor model (3D killing assay) are shown in Fig. 7-2.
- Fig. 7-1 the SKOV3 sphere to which NK cells were not added was indicated as nega.
- TUDCA concentration range of TUDCA was widened and the evaluation in the solid tumor model was added, it was preferable to use TUDCA added before freezing at a concentration between 2,400 ⁇ M and 267 ⁇ M, and the recovery rate was high and the recovery rate was particularly high when used at 800 ⁇ M.
- the injury activity for the solid tumor model was high.
- Example 8 (8-1) Count the number of viable cells of highly active NK cells obtained by the procedure described in the method for culturing and recovering highly active NK cells, and suspend them with STEM-CELL BANKER so as to be 1x10 7 cells / mL. It became turbid and was cryopreserved at -80 ° C.
- the highly active NK cells were frozen for more than 48 hours 37 ° C., was thawed in a water bath, including (1) Plasma-Lyte A, (2) 1.48mM MgCl 2 ⁇ 6H 2 O ( Nacalai Tesque, 20909-55) PBS (-), (3) PBS (-), (4) KBM501 medium, (5) 62.2mg / L CaCl 2 ⁇ 2H 2 O ( Nacalai Tesque, 08895-15) Plasma-Lyte a containing, (6) Plasma-Lyte A with 0.1% glucose (50% glucose, Termo), (7) glucose, (8) RPMI medium without serum components (Nacalai Tesque, 09892-15), (9) RPMI medium with glucose (9) It was diluted 10-fold in Nacalai Tesque, 30264-85), and (1) to (4) were incubated at room temperature for 2 hours, and (1) and (5) to (9) were incubated at 37 ° C for 3 hours. After that, the measurement was performed by
- lactic acid was added according to the lactic acid concentration of the lacto Ringer's solution, and it was confirmed on the Lithomas test paper that it was neutral.
- DDL 4 was added according to the DDL 4 concentration of HBSS. After that, the measurement was performed by the method described in the staining method using 7-AAD, and the analysis was performed with FlowJo software.
- Plasma-Lyte A (2) saline solution, (3) RPMI1640 medium, (4) lactolin gel, (5) 0.423 mM CaCl 2 , prepared with Plasma-Lyte A, (6) Diluted 10-fold with 1.36 mM CaCl 2 and allowed to stand at 37 ° C for 3 hours.
- CaCl 2 of (5) was added to RPMI1640 medium, and CaCl 2 of (6) was added according to Lacto Ringer's solution. After that, the measurement was performed by the method described in the staining method using 7-AAD, and the analysis was performed with FlowJo software.
- Example 9 (9-1) Count the number of viable cells of highly active NK cells obtained by the procedure described in the method for culturing and recovering highly active NK cells, and suspend them with STEM-CELL BANKER so as to be 4x10 7 cells / mL. It became turbid and was cryopreserved at -80 ° C. Highly active NK cells frozen for 48 hours or more were thawed in a water bath at 37 ° C., diluted 10-fold with Plasma-Lyte A containing 3000 units / mL IL-2, and allowed to stand at room temperature for up to 6 hours. Cytotoxic activity was analyzed at points 2 hours, 5 hours, and 6 hours after thawing.
- NK cells and K562 cells were added to a 96-well plate (IWAKI, 4870-800SP) so that the cell ratio was 1: 1 by the method described in Example 9-1 (b), and then mixed.
- the reaction was carried out at 37 ° C. under 5% CO 2 for 2 hours.
- the number of viable cells of highly active NK cells obtained by the procedure described in the method for culturing and recovering highly active NK cells was counted, suspended in STEM-CELLBANKER so as to be 4x10 7 cells / mL, and -80 ° C. It was cryopreserved in.
- Highly active NK cells frozen for 48 hours or more were thawed in a water bath at 37 ° C., diluted 10-fold with Plasma-Lyte A containing 3000 units / mL IL-2, and allowed to stand at room temperature for up to 4 hours.
- Viability transition Thawed cells were mixed well at each point , 1x10 5 cells were separated, measured by the method described in the staining method with 7-AAD, and analyzed with FlowJo software.
- cytotoxic activity a group in which NK cells and K562 cells were reacted, a group in which only K562 cells were used as a negative control, and a group in which K562 cells were fixed with 10% formalin were prepared as a positive control.
- NK cells The required amount of NK cells was collected based on the number of viable cells at the time of freezing, and then adjusted to a concentration of 1x10 6 cells / mL with 10% FBS / RPMI1640.
- K562 cells were suspended in serum-free RPMI1640 medium, stained with PKH26 Red Fluorescent Cell Linker Kit, and then prepared to 2x10 6 cells / mL with 10% FBS / RPMI1640.
- NK cells and K562 cells were added to and mixed in a 96-well plate (IWAKI, 4870-800SP) so that the cell ratio was 1: 2, 1: 1, 2: 1, 4: 1, 37 ° C, 5%. Reacted under CO 2 for 2 hours. After completion of the reaction, measurement was performed by the method described in the staining method using 7-AAD, and analysis was performed with FlowJo software to calculate the cytotoxic activity rate (% Lysis).
- NK cells and K562 cells were prepared by the method described in b).
- Cell damage activity (1), and 96-well plates (IWAKI, 4870-800SP) were prepared so that the cell ratio of NK cells and K562 cells was 1: 1.
- the cells were reacted at 37 ° C. under 5% CO 2 for 2 hours, 4 hours, 6 hours and 8 hours.
- measurement was performed by the method described in the staining method using 7-AAD, and analysis was performed with FlowJo software to calculate the cytotoxic activity rate (% Lysis).
- cytotoxic activity was measured. Specifically, NK cells and K562 cells were added to a 96-well plate (IWAKI, 4870-800SP) so as to have a cell ratio of 1: 1 and mixed, and then reacted at 37 ° C. under 5% CO 2 for 2 hours. rice field. After completion of the reaction, measurement was performed by the method described in the staining method using 7-AAD, and analysis was performed with FlowJo software to calculate the cytotoxic activity rate (% Lysis).
- Example 10 (10-1) Culturing method of highly active NK cells, counting the number of viable cells of highly active NK cells obtained by the procedures described in recovery method 1 and recovery method 2, 1x10 7 cells / mL (1.5 mL tube). Suspend in STEM-CELLBANKER to obtain recovery method 1, i.e. wash with PBS at the time of recovery), 4x10 7 cells / mL (5 mL vial; recovery method 2, i.e. wash with KBM501 medium at the time of recovery), -80 It was cryopreserved at ° C. Highly active NK cells frozen for 48 hours or longer were thawed at room temperature.
- Plasma-Lyte A or KBM501 medium Immediately after the thawed cells are completely dissolved, 10 times in Plasma-Lyte A or KBM501 medium at 5 minutes, 10 minutes, 15 minutes, 20 minutes, 25 minutes, 30 minutes, 60 minutes, 120 minutes, and 180 minutes. It was diluted and allowed to stand at room temperature for up to 180 minutes. After diluting to 180 minutes, the measurement was performed by the method described in the staining method using 7-AAD, and the analysis was performed with FlowJo software.
- Plasma-Lyte A or KBM501 medium Immediately after the thawed cells are completely dissolved, 10 times in Plasma-Lyte A or KBM501 medium at 5 minutes, 10 minutes, 15 minutes, 20 minutes, 25 minutes, 30 minutes, 60 minutes, 120 minutes, and 180 minutes. It was diluted and allowed to stand at room temperature for up to 180 minutes. After diluting to 180 minutes, the measurement was performed by the method described in the staining method using 7-AAD, and the analysis was performed with FlowJo software.
- Example 11 1x10 7 cells / mL (1.5 mL tube), 4x10 7 cells / The cells were suspended in STEM-CELLBANKER so as to be mL (5 mL vial), and cryopreserved at -80 ° C. Highly active NK cells frozen for 48 hours or longer were thawed in a water bath at 37 ° C. Immediately after it was completely dissolved, it was diluted 10-fold in Plasma-Lyte A or KBM501 medium and allowed to stand at room temperature for up to 6 hours. Immediately after dilution, 1x10 5 cells were fractionated at points of 1 hour, 2 hours, 3 hours, and 6 hours, measured by the method described in the staining method with 7-AAD, and analyzed with FlowJo software.
- Example 12 (12-1) Count the number of viable cells of highly active NK cells obtained by the procedure described in the method for culturing and recovering highly active NK cells, and suspend them with STEM-CELL BANKER so as to be 4x10 7 cells / mL. It became turbid and was cryopreserved at -80 ° C. Highly active NK cells frozen for 48 hours or longer were thawed in a water bath at 37 ° C. Immediately after complete dissolution, Plasma-Lyte A was diluted 10-fold with 80%, 50% and 10% Plasma-Lyte A diluted with Ultra Pure Distilled Water (invitrogen, 10977-015) at room temperature and 37 ° C, respectively.
- Ultra Pure Distilled Water invitrogen, 10977-015
- Plasma-Lyte A was diluted with physiological saline and diluted 10-fold with 80%, 50%, 10% Plasma-Lyte A, 3 at room temperature and 37 ° C, respectively. It was left to stand for hours.
- Plasma-Lyte A was diluted with physiological saline or diluted 10-fold with physiological saline, and allowed to stand at room temperature and 37 ° C for up to 3 hours, respectively.
- (12-7) The cells were treated and analyzed in the same manner as in (12-6). However, the cells were diluted 10-fold with each solution and allowed to stand at 37 ° C. for up to 3 hours.
- Viability could be maintained with the NaCl solution regardless of whether the solution used for thawing was hypotonic or hypertonic. Further, even with an isotonic solution using a monosaccharide or a polysaccharide, Viability could be maintained at room temperature or for a short period of time. On the other hand, 100 mM MgCl 2 was inferior in Viability.
Abstract
Description
[1]以下の工程を含む、細胞の処理方法:
(1)体外で活性化した細胞を、細胞培養用の培地で回収し;
(2)回収した細胞を凍結保存のための液に懸濁し;
(3)懸濁した細胞を、凍結する。
[2]工程(1)が、胆汁酸およびフェニル酪酸からなる群より選択されるいずれかを添加した培地による処理を含む、[1]に記載の方法。
[3]さらに以下の工程を含む、[1]または[2]に記載の方法:
(4)凍結保存した細胞を、解凍し、解凍溶媒Iに懸濁する。
[4] 解凍溶媒Iが、以下を含む水溶液である、[1]~[3]のいずれか1項に記載の方法:
・塩化ナトリウム 9.00 ~108mM、
・グルコン酸ナトリウム 2.30~27.7mM、
・酢酸ナトリウム 2.70~32.5mM、
・塩化カリウム 0.496~5.96mM、および
・塩化マグネシウム 0.148~1.78mM。
[5] 解凍溶媒Iが、以下の少なくとも1つを満たす、[1]~[4]のいずれか1項に記載の方法:
・カルシウムイオンを0.423mM以上の濃度で含まない、
・グルコースを5.55mM以上の濃度で含まない、および
・乳酸塩を27.7mM以上の濃度で含まない。
[6] 以下を含む、高活性NK細胞を懸濁するための液:
・塩化ナトリウム 9.00 ~108mM、
・グルコン酸ナトリウム 2.30~27.7mM、
・酢酸ナトリウム 2.70~32.5mM、
・塩化カリウム 0.496~5.96mM、および
・塩化マグネシウム 0.148~1.78mM。
[7] 凍結保存のための液に懸濁して凍結された高活性NK細胞を懸濁するためのものである、[6]に記載の液。
[8] 高活性NK細胞、凍結保存のための液、および[6]に記載された液を含む、医薬組成物。
[9] 以下の工程を含む、細胞を含む医薬組成物の製造方法:
(1)体外で活性化した細胞を、細胞培養用の培地で回収し;
(2)回収した細胞を凍結保存のための液に懸濁し;
(3)懸濁した細胞を、凍結する。
[10] 工程(1)が、胆汁酸およびフェニル酪酸からなる群より選択されるいずれかを添加した培地による処理を含む、[9]に記載の製造方法。
[適用できる細胞]
本発明は、種々の細胞に適用することができる。本発明が好ましく適用できる細胞の一つは、体外で何らかのサイトカインを用いることによる活性化操作を経た細胞であり、このような細胞には、細胞傷害活性の高いNK細胞(高活性NK細胞)等が含まれる。活性化操作は、典型的にはインターロイキン(IL)-2を含む培地を用いて細胞をインキュベートすることに拠る。
本発明が好ましく適用できる高活性NK細胞等の原材料は、末梢血、臍帯血、骨髄および/またはリンパ節、アフェレーシス法により採取された血液(アフェレーシス血液)であってよい。また原材料は、胚性幹細胞、成体幹細胞および人工多能性幹(iPS)細胞からなるグループから選択されるいずれかの幹細胞由来の造血幹細胞、臍帯血由来の造血幹細胞、末梢血由来の造血幹細胞、骨髄血由来の造血幹細胞、臍帯血単核球、末梢血単核球からなる群から選択される少なくとも1種類の細胞から調製されたものであってもよい。原材料のドナーは、高活性NK細胞等による免疫治療を受ける患者自身、該患者の近縁者、または患者とは血縁関係のない健常者である場合がある。ドナーは複数であってもよい。
高活性NK細胞等を培養するために用いる培地は、KBM501培地(コージンバイオ株式会社。IL-2を1,750JRU/ mL含む。)、コスメディウム008(コスモバイオ。IL-2を1,750JRU/ mL含む。)、FKCM101(フコク。IL-2不含、またはIL-2を175IU/mL含む。)、CellGro SCGM培地(セルジェニックス、岩井化学薬品株式会社)、X-VIVO15培地(ロンザ、タカラバイオ株式会社)、Gibco(登録商標) CTS(登録商標) AIM V(登録商標) Medium(サーモフィッシャーサイエンティフィック。T細胞および樹状細胞を増殖・操作するための既知組成の無血清培地)、CTS OpTmizer T Cell Expansion Basal Medium(サーモフィッシャーサイエンティフィック。ヒトTリンパ球の成長および増殖用)、IMDM、MEM、DMEM、RPMI-1640等を含むが、これらに限定されない。好ましい例は、KBM501培地、FKCM101またはコスメディウム008である。なお、本発明に関し、細胞について培養(する)というときは、特に記載した場合を除き、細胞の生存維持、細胞の増幅、および細胞の活性化からなる群より選択されるいずれかの目的のために細胞を一定時間、培地またはそれに準じた液の中で維持することをいう。処理を特定の温度で一定時間行う場合に、インキュベート(する)ということがある。
(1)CD16陽性、CD56高発現性、かつCD57陰性である。
(2)NKG2C陽性、NKG2A陰性~低発現性、およびCD94陽性である。
(3)該NK細胞をエフェクター細胞(E)とし、K562細胞を標的細胞(T)として混合比(E:T)1:1で共培養した場合の細胞傷害活性が50%以上である。
健常人由来末梢血単核球から、CD3ビーズ(例えば、CliniMACS CD3, ミルテニーバイオテク社, カタログ番号130-017-601)、LDカラム(例えば、ミルテニーバイオテク,カタログ番号130-042-901)および分離バッファー(例えば、0.5%ヒトAB型血清 (非働化処理したもの)、2mM EDTAを含むPBS)を用いてCD3陽性細胞を除去した細胞集団を、適切な培地(例えば、5%ヒトAB型血清(非働化処理したもの)を添加したコスメディウム008)で14日間培養して得られ、下記(1)および(3)の特徴を備えるNK細胞:
(1)CD16陽性、CD56高発現性、かつCD57陰性である。
(3)該NK細胞をエフェクター細胞(E)とし、K562細胞を標的細胞(T)として混合比(E:T)1:1で共培養した場合の細胞傷害活性が50%以上である。
CCR5陽性、CCR6陽性およびCXCR3陽性であり且つCD3陰性である細胞。
CCR5陽性、CCR6陽性、CXCR3陽性、Integrin α1陽性、Integrin α3陽性およびIntegrin β3陰性であり且つCD3陰性である細胞。あるいは、CCR5陽性、CCR6陽性、CXCR3陽性、CD11a高発現性およびCD11c高発現性であり且つCD3陰性であり、高発現性は、末梢血から得た、実質的な培養を行なっていないNK細胞の集団における発現との比較により判断される、細胞。
新鮮末梢血から、または凍結アフェレーシス血液から得た単核球にCD3 beads (例えば、CliniMACS CD3, ミルテニーバイオテク, 130-017-601(1x107細胞あたり5μL))、および凍結アフェレーシス血液を使用した場合はさらにCD34 beads(例えば、CliniMACS CD34, ミルテニーバイオテク, 130-017-501(1x107細胞あたり2.5μL))を添加・懸濁し、4℃, 15分間インキュベート後、分離バッファー(例えば、0.5%ヒトAB型血清 (56℃で30分の非働化処理したもの)、2 mM EDTAを含むPBS)を加えてよく懸濁し、遠心する。上清を除去し、LDカラム(例えば、ミルテニーバイオテク, 130-042-901)1カラムあたり最大1x108 cellsまでの細胞数となるように0.5 mLの分離バッファーに懸濁する。分離バッファー 2 mLをあらかじめ添加したのち、LDカラムに細胞懸濁液を添加して、LDカラムからの溶出液を回収した。さらに分離バッファー 1 mLをLDカラムに添加し、溶出液を回収する。回収した液の遠心分離を行い、上清を除去後、末梢血を使用した場合は5x105 cells/mL、凍結アフェレーシス血液を使用した場合は1x106 cells/mLとなるように適切な培地(例えば、5%ヒトAB型血清(56℃で30分の非働化処理したもの)あるいは5%UltraGRO (AventaCell、HPCPLCRL10) に2U/mL ヘパリンナトリウムを添加したもの、のいずれか一方を含むKBM501培地)に細胞を懸濁し、適宜培地交換しながら、14日目まで培養する。
本発明に関し、高活性NK細胞等について、活性または細胞傷害活性というときは、特に記載した場合を除き、対象細胞(エフェクター細胞、E)の標的細胞(T)に対する溶解能を指す。細胞傷害活性は、エフェクター細胞により死に至った標的細胞の百分率(%)で表すことができ、次式により求められる。
本発明においては、後述する凍結工程に先立ち、凍結すべき高活性NK細胞等を培養系から回収する。回収は、遠心分離して培地と細胞を分離することにより行うことができる。必要に応じ、培養系に適切な濃度のEDTAを加え、接着した細胞を培養容器表面から剥離してもよい。また、培地をしたあとの培養容器表面を適切な溶液で洗浄して、残った細胞を得てもよい。得られた細胞は、必要に応じ、適切な溶液で洗浄し、適切な溶液に懸濁する。
本発明においては、後述する凍結工程に先立ち、凍結すべき高活性NK細胞等を前処理してもよい。前処理とは、回収した細胞を添加剤を含む溶液に懸濁することである。前処理は、添加剤を含む溶液で回収することを含む。
本発明においては、回収され、好ましくは前処理された細胞は、通常の手順によって、凍結される。具体的には、必要に応じ細胞数や生存率を確認し、遠心分離して上清を除去した後、適切な細胞密度になるように凍結保存液に細胞を懸濁する。細胞懸濁液を凍結保存用の容器に分注した後、-80℃のディープフリーザーで凍結し、保存する。必要に応じ、液体窒素タンクで凍結保存する。
本発明においては、凍結保存された細胞は、種々の手順によって解凍できる。例えば、細胞の入った凍結保存用の容器を37℃の温浴などで、必要に応じ振りながら迅速に解凍できる。あるいは、冷凍庫から取り出した後に積極的な加温をせず、室温に放置して自然解凍できる。解凍後の細胞は適切な解凍時溶媒Iに混和する。必要に応じ、遠心分離を行って上清を除去し、適量の解凍時溶媒IIに懸濁し、培養や活性化処理を行うことができる。
本発明においては、凍結保存のための液に懸濁して凍結した細胞を、解凍し、凍結保存のための液とともに希釈する際に用いる溶液を、解凍時溶媒Iという。本発明により回収し、必要に応じ前処理を行って凍結保存された細胞に対しては、解凍時溶媒Iとして種々のものを用いうる。
・塩化ナトリウム 9.00 ~108mM
・グルコン酸ナトリウム 2.30~27.7mM
・酢酸ナトリウム 2.70~32.5mM
・塩化カリウム 0.496~5.96mM
・塩化マグネシウム 0.148~1.78mM
・塩化ナトリウム 85.5 ~94.5mM
・グルコン酸ナトリウム 21.8~24.2mM
・酢酸ナトリウム 25.6~28.5mM
・塩化カリウム 4.71~5.21mM
・塩化マグネシウム 1.40~1.55mM
あるいは、解凍時溶媒Iは、具体的には以下を含む液である。
・塩化ナトリウム 146.3 ~161.7mM
本発明においては、凍結した細胞を解凍時溶媒Iを用いて解凍した後、さらに解凍時溶媒IIを用いて、細胞を培養し、または活性化することができる。本発明においては、解凍時溶媒Iに懸濁した細胞を回収し、培養または活性化等のために再度懸濁するために用いる溶液を、解凍時溶媒IIという。解凍時溶媒IIとしては、目的に応じ、種々のものを用いることができる。
本発明は、適切な方法で回収され、必要に応じ前処理され、凍結保存された高活性NK細胞等を含む、医薬組成物を提供する。
注射剤(細胞懸濁液)
構成細胞:高活性NK細胞等
含量:6×106個~4.8×109cells/60kg
複合電解質液 10~45%
塩化ナトリウム液 10~45%
20~30%ヒト血清アルブミン液 5~30%
ジメチルスルホキシド 2~15%
その他
あるいは、
医薬添加物として許容できる凍結保存液 100%
凍結された組成物が完全に解凍するまで、37℃の恒温水槽等で解凍する。解凍後速やかに無菌的に、別途準備した医薬添加物として許容できる等張液に懸濁する。
解凍後の有効期間は、室温で保存するとき、6時間、好ましくは4時間である。
A) 高活性NK細胞の培養方法
原材料1: 末梢血利用の場合
健常人ボランティアより末梢血を採取し、Ficoll(GEヘルスケア、17144002)を用いた密度勾配遠心により末梢血単核球(PBMCs: Peripheral blood mononuclear cells)を単離した。
凍結アフェレーシス血液(HemaCare, PB001CLP)を解凍し、Lovo Cell Processing System(FRESENIUS KABI)を使用して洗浄と濃縮を行い、PBMCsを得た。
以下では、PBMCsからこの培養工程を経ることにより得た細胞を、「高活性化NK細胞様CD3陰性細胞(Highly activated NK cell-like CD3-negative cells)」または単に「高活性NK細胞」と称する。
※2:CliniMACS CD34, ミルテニーバイオテク, 130-017-501(1x107細胞あたり2.5μL)
※3: 0.5%ヒトAB型血清 (コスモバイオ, 12181301, 56℃で30分の非働化処理したもの)、2 mM EDTA(サーモフィッシャーサイエンティフィック, 15575-020)を含むPBS(ナカライテスク、14249-24)
※4: 5%ヒトAB型血清(コスモバイオ, 12181301, 56℃で30分の非働化処理したもの)あるいは5%UltraGRO (AventaCell、HPCPLCRL10) に2U/mL ヘパリンナトリウム(ニプロ)を添加したもの、のいずれか一方を含むKBM501(コージンバイオ,16025015)
回収方法1: 従来の方法
培養14日目に培養液を回収、さらに培養容器に1mM EDTAを加え接着した細胞を剥離し、剥離細胞を回収したあとの培養容器をPBS (ナカライテスク、14249-24)で洗浄した。すべての細胞回収液を遠心後、PBSで洗浄、再懸濁した。
培養14日目に培養液を回収、さらに培養容器に1mM EDTAを加え接着した細胞を剥離し、剥離細胞を回収したあとの培養容器をKBM501培地で洗浄した。すべての細胞回収液を遠心後、KBM501培地で洗浄、再懸濁した。
各条件下で解凍した高活性NK細胞 1x105cells/wellを96ウェルプレート(IWAKI, 4870-800SP)にて遠心分離し、上清を除去後、PBSで希釈した7-Amino-Actinomycin D(7-AAD)溶液(Beckman Coulter, A07704)を添加、懸濁し、室温(15~25℃をいう。以下の実験において同じ。)で20分間インキュベートした。染色後の細胞をフローサイトメーター(BD LSR Fortessa、BDバイオサイエンス社)を用いて測定を行った。
[参考例]
高活性NK細胞の培養方法、回収方法1に記載した手順にて得られた高活性NK細胞、PBMC、K562(ヒト慢性骨髄性白血病細胞株)、THP-1(ヒト急性単球性白血病細胞株)をMito-FerroGreen(同仁化学研究所、M489)にて反応させ、フローサイトメーター(BD LSR Fortessa、BDバイオサイエンス社)を用いて測定を行った。
<2> Z-Vadを含むKBM501培地に希釈、37℃で3時間
<3> Methylprednisoloneを含むKBM501培地に希釈、37℃で3時間
<4> Dexamethasoneを含むKBM501 培地に希釈、37℃で3時間
<5> KBM501培地に希釈、4℃で3時間
<6> Methylprednisoloneを含むKBM501培地に希釈、4℃で3時間静置後、37℃で3時間
<7> Dexamethasoneを含むKBM501培地に希釈、4℃で3時間静置後、37℃で3時間
(1-1) 健常人ボランティア2名それぞれから高活性NK細胞の培養方法、回収方法1に記載した手順にて得られた高活性NK細胞の生細胞数をカウントし、それぞれ1x107cells, 8x106cellsを1mLのSTEM-CELLBANKER (ZENOAQ、CB045)で懸濁し、-80℃で凍結した。48時間以上凍結させたNK細胞を37℃、ウォーターバスにて解凍したのち、解凍直後として1x105cellsを96ウェルプレート(IWAKI)に分取した。また、KBM501培地、3500単位/mL IL-2(セロイク(登録商標)注射用40, 武田薬品工業)、139.9mMマルトースを含むラクトリンゲル(扶桑薬品工業)、3500単位/mL IL-2を含むPlasma-Lyte A(Baxter)、 5.02mg/mL グルコン酸ナトリウム(ナカライ、16720-22)を含むKBM501培地で10倍希釈となるようにそれぞれ懸濁し、37℃、5% CO2下で3時間インキュベートした。解凍直後の細胞は分取後速やかに、そのほか4群は3時間インキュベート後に遠心分離し、7-AADによる染色方法に記載した方法で測定を行い、FlowJoソフトウェア(FLOWJO, LLC)で解析し、生細胞率を算出した。
高活性NK細胞の培養方法、回収方法1に記載した手順にて得られた高活性NK細胞の生細胞をカウントし5x106cells、1x107cellsを1mLのSTEM-CELLBANKERで懸濁し-80℃で凍結した。48時間以上凍結させたNK細胞を37℃、ウォーターバスにて解凍したのち、解凍直後として1x105cellsを96ウェルプレートに分取した。また、KBM501培地、3500単位/mL IL-2を含むラクトリンゲル、3500単位/mL を含むPlasma-Lyte A、40% Serum(ヒトAB型血清)を含むPlasma-Lyte Aで10倍希釈となるようにそれぞれ懸濁し、37℃、5% CO2下で3時間インキュベートした。解凍直後の細胞は分取後速やかに、そのほか4群は3時間インキュベート後に遠心分離し、7-AADによる染色方法に記載した方法で測定を行い、FlowJoソフトウェアで解析し、生細胞率を算出した。
高活性NK細胞の培養方法、回収方法1に記載した手順にて得られた高活性NK細胞の生細胞数をカウントし1x107cellsを1mLのSTEM-CELLBANKERで懸濁し-80℃で凍結した。48時間以上凍結させたNK細胞を37℃、ウォーターバスにて解凍したのち、3500単位/mL IL-2 (イムネース、塩野義製薬株式会社)を含むPlasma-Lyte A(溶媒(1))、またはKBM501培地(溶媒(2))にて希釈し、次に記載する群ごとに希釈後の生細胞数および生細胞率、細胞傷害活性率(%Lysis)を算出した。
<1> 溶媒(1)にて10倍希釈、37℃で1時間静置後、等量のKBM501培地を添加し37℃で3時間インキュベート
<2> 溶媒(1)にて10倍希釈、37℃で1時間静置後、等量のIL-2を含むラクトリンゲルを添加し37℃で3時間インキュベート
<3> 溶媒(1)にて10倍希釈、37℃で1時間静置後、等量のKBM501培地を添加し37℃で一晩インキュベート
<4> 溶媒(1)にて10倍希釈、37℃で1時間静置後、等量のIL-2を含むラクトリンゲルを添加し37℃で一晩インキュベート
<5> 溶媒(1)にて10倍希釈、37℃で3時間静置
<6> 溶媒(2)にて10倍希釈、37℃で3時間静置
<7> 溶媒(2)にて10倍希釈、37℃で一晩静置
細胞傷害活性の測定には、NK細胞とK562細胞を反応させた群、陰性コントロールとしてK562細胞のみの群、陽性コントロールとしてK562細胞を10%ホルマリンで固定した群を用意した。
各群記載した時間インキュベートしたあと、細胞を回収し、10%FBS/RPMI1640にて2x106cells/mLの濃度に調製した。
K562細胞(ヒト慢性骨髄性白血病細胞株)を血清成分を含まないRPMI1640培地にて懸濁したK562細胞をPKH26 Red Fluorescent Cell Linker Kit (Sigma, PKH26GL-1KT) を用いて染色し、最終的に10%FBS/RPMI1640にて2x106 cells/mLとなるように調製した。
※5: 細胞傷害活性率=(SKOV3細胞死細胞率-陰性コントロール死細胞率)/(陽性コントロール死細胞率-陰性コントロール死細胞率)×100
高活性NK細胞の培養方法、回収方法1に記載した手順にて得られた高活性NK細胞の生細胞数をカウントし1x106 cells/mLとなるように以下に挙げる6種の溶媒で懸濁し、低吸着の6ウェルプレート(IWAKI、4810-800SP)に播種することにより凍結前処理を行った。前処理の溶媒には(1)10μM 4-フェニル酪酸(4-PBA、東京化成工業株式会社、P0643)を含むKBM501培地、(2)100μM 4-フェニル酪酸を含むKBM501培地、(3)Plasma-Lyte A、(4)3000単位/mL IL-2 (イムネース、塩野義製薬株式会社)を含むPlasma-Lyte A、(5)10μM Salubrinal (TOCRIS、 2347)を含むPlasma-Lyte A、(6)23mM グルコン酸ナトリウムを含むPBSを使用し、各溶媒で懸濁した細胞を(1)、(2)群は37℃、5% CO2下、(3)~(6)群は室温にて2時間インキュベートした。前処理後、処理時の細胞数をもとに1x107cells/mLとなるようにSTEM-CELLBANKERで懸濁し、-80℃で凍結保存した。48時間以上凍結させた前処理済みのNK細胞を37℃、ウォーターバスにて解凍し、下記の通り希釈した。解凍後の希釈、インキュベートはすべて低吸着の6ウェルプレートにて行った。
1000単位/mL IL-2を含むPlasma-Lyte Aまたは1000単位/mL IL-2および100μM 4-PBSを含むPlasma-Lyte Aにそれぞれ11倍希釈し、室温で1時間インキュベート後、KBM501培地に5倍希釈した。
Plasma-Lyte Aに11倍希釈し、室温で1時間インキュベート後、RPMI培地*6または2400単位/mL IL-2を含むRPMI培地にそれぞれ5倍希釈した。
1000単位/mL IL-2を含むPlasma-Lyte Aまたは1000単位/mL IL-2および100μM 4-PBAを含むPlasma-Lyte Aにそれぞれ11倍希釈し、室温で1時間インキュベート後、KBM501培地に5倍希釈した。
Plasma-Lyte Aに11倍希釈し、室温あるいは37℃、5% CO2下で1時間インキュベート後、それぞれ RPMI培地、2400単位/mL IL-2を含むRPMI培地に5倍希釈した。
1000単位/mL IL-2を含むPlasma-Lyte A、1000単位/mL IL-2および100μM 4-PBAを含むPlasma-Lyte Aにそれぞれ11倍希釈し、室温で1時間インキュベート後、KBM501培地に5倍希釈した。
Plasma-Lyte Aに11倍希釈し、室温あるいは37℃、5% CO2下で1時間インキュベート後、それぞれRPMI培地、2400単位/mL IL-2を含むRPMI培地に5倍希釈した。
高活性NK細胞の培養方法、回収方法1と回収方法2に記載した手順にて得られた高活性NK細胞の生細胞数をカウントし1x106 cells/mLとなるように各種溶媒で懸濁し、低吸着の6ウェルプレートに播種することにより凍結前処理を行った。回収方法1で得られたNK細胞はPBSにて懸濁し、室温で1時間インキュベートした。回収方法2で得られたNK細胞は(1)KBM501培地、(2)30μM 4-フェニル酪酸を含むKBM501培地、(3)30μM Tauroursodeoxycholic Acid Dihydrate (TUDCA、東京化成工業株式会社、T1567)を含むKBM501培地、(4)30μM 4-フェニル酪酸および30μM TUDCAを含むKBM501培地で懸濁した細胞を37℃、5% CO2下で2時間インキュベートした。前処理後、処理時の細胞数をもとに1x107 cells/mLとなるようにSTEM-CELLBANKERで懸濁し、-80℃で凍結保存した。48時間以上凍結させた前処理済みの高活性NK細胞を37℃、ウォーターバスにて解凍し、各群それぞれPlasma-Lyte Aに11倍希釈、室温で1時間インキュベートした。1時間後、緩やかに懸濁し生細胞数をカウントした。さらにKBM501培地に5倍希釈し37℃、5% CO2下で2時間インキュベート後、生細胞数をカウントし凍結時の細胞数に対する回収率として算出した。
高活性NK細胞の培養方法、回収方法2に記載した手順にて得られた高活性NK細胞の生細胞数をカウントし1x106 cells/mLとなるようにKBM501培地のみ、或いはTUDCA(10μM, 30μM, 90μM, 270μM, 810μM)を含むKBM501培地で懸濁し、低吸着の6ウェルプレートに播種、37℃、5% CO2下で2時間インキュベートし凍結前処理を行った。前処理後、処理時の細胞数をもとに1x107cells/mLとなるようにSTEM-CELLBANKERで懸濁し、-80℃で凍結保存した。48時間以上凍結させた前処理済みのNK細胞を37℃、ウォーターバスにて解凍し、各群それぞれPlasma-Lyte Aを10倍量加え、室温で3時間までインキュベートした。1時間後と3時間後、緩やかに懸濁し生細胞数をカウントした。また、1時間後にはKBM501培地に5倍希釈し37℃、5% CO2下で2時間インキュベート後、生細胞数をカウントした。解凍後各ポイントでの生細胞数から凍結時の細胞数に対する回収率として算出した。また、各タイムポイントで高活性NK細胞の細胞傷害活性の測定を行った。
細胞傷害活性の測定には、NK細胞とK562細胞を反応させた群、陰性コントロールとしてK562細胞のみの群、陽性コントロールとしてK562細胞を10%ホルマリンで固定した群を用意した。
記載の方法で解凍、希釈した細胞を凍結時の生細胞数をもとに必要量分取した後、10%FBS/RPMI1640にて2x106cells/ mLの濃度に調製した。
K562細胞を無血清RPMI1640培地にて懸濁し、PKH26 Red Fluorescent Cell Linker Kitを用いて染色したのち、10%FBS/RPMI1640にて2x106 cells/mLとなるように調製した。
高活性NK細胞の培養方法、回収方法2に記載した手順にて得られた高活性NK細胞の生細胞数をカウントし1x106 cells/mLとなるようにKBM501培地のみ、266μM, 810μM, 2400μM TUDCAを含むKBM501培地、2.4% DMSO(ナカライテスク、13445-74) を含むKBM501培地で懸濁、低吸着の6ウェルプレートに播種、37℃、5% CO2下で2時間インキュベートし凍結前処理を行った。前処理後、処理時の細胞数をもとに1x107cells/mLとなるようにSTEM-CELLBANKERで懸濁し、-80℃で凍結保存した。48時間以上凍結させた前処理済みのNK細胞を37℃、ウォーターバスにて解凍し、各群それぞれPlasma-Lyte Aまたは3000単位/mL IL-2を含むPlasma-Lyte Aに11倍希釈、室温で3時間までインキュベートした。1時間後と3時間後、緩やかに懸濁し生細胞数をカウントした。また、1時間後にはKBM501培地に5倍希釈し37℃、5% CO2下で2時間インキュベート後、生細胞数をカウントした。解凍後各ポイントでの生細胞数から凍結時の細胞数に対する回収率として算出した。
SKOV3細胞(ヒト卵巣がん細胞株)を10%FBS/RPMI1640にて3x104 cells/mLとなるように調製し、96ウェルプレートの1ウェルあたり3x103/100μLを播種した。 37℃、5% CO2下で3日間培養しsphereを作成した。
(8-1) 高活性NK細胞の培養方法、回収方法2に記載した手順にて得られた高活性NK細胞の生細胞数をカウントし1x107 cells/mLとなるようにSTEM-CELLBANKERで懸濁し、-80℃で凍結保存した。48時間以上凍結させた高活性NK細胞を37℃、ウォーターバスにて解凍し、(1)Plasma-Lyte A、(2)1.48mM MgCl2・6H2O(ナカライテスク、20909-55)を含むPBS(-)、(3)PBS(-)、(4)KBM501培地、(5)62.2mg/L CaCl2・2H2O(ナカライテスク、08895-15)を含むPlasma-Lyte A、(6)0.1%グルコース(50%ブドウ糖、テルモ)を含むPlasma-Lyte A、(7)グルコース、(8)血清成分を含まないRPMI培地(ナカライテスク、09892-15)、(9)グルコースを含むRPMI培地(ナカライテスク、30264-85)に10倍希釈し、(1)~(4)は室温で2時間、(1)と(5)~(9)は37℃で3時間インキュベートした。その後7-AADによる染色方法に記載した方法で測定を行い、FlowJoソフトウェアで解析した。
(9-1) 高活性NK細胞の培養方法、回収方法2に記載した手順にて得られた高活性NK細胞の生細胞数をカウントし4x107 cells/mLとなるようにSTEM-CELLBANKERで懸濁し、-80℃で凍結保存した。48時間以上凍結させた高活性NK細胞を37℃、ウォーターバスにて解凍し、3000単位/mL IL-2を含むPlasma-Lyte Aに10倍希釈、室温で6時間まで静置した。解凍2時間後、5時間後、6時間後のポイントで細胞傷害活性についてそれぞれ解析を行った。細胞傷害活性は実施例9-1 (b)に記載した方法にてNK細胞とK562細胞を細胞比で1:1となるように96ウェルプレート(IWAKI, 4870-800SP)に添加、混合したのち、37℃、5% CO2下で2時間反応させた。
各ポイントで解凍細胞をよく混和し、1x105cellsを分取、7-AADによる染色方法に記載した方法で測定を行い、FlowJoソフトウェアで解析した。
細胞傷害活性の測定には、NK細胞とK562細胞を反応させた群、陰性コントロールとしてK562細胞のみの群、陽性コントロールとしてK562細胞を10%ホルマリンで固定した群を用意した。
NK細胞を凍結時の生細胞数をもとに必要量分取した後、10%FBS/RPMI1640にて1x106cells/mLの濃度に調製した。
K562細胞を無血清RPMI1640培地にて懸濁し、PKH26 Red Fluorescent Cell Linker Kitを用いて染色したのち、10%FBS/RPMI1640にて2x106 cells/mLとなるように調製した。
上記b). 細胞傷害活性(1)に記載した方法でNK細胞とK562細胞を調製し、NK細胞とK562細胞を細胞比で1:1となるように96ウェルプレート(IWAKI, 4870-800SP)に添加、混合したのち、37℃、5% CO2下で2時間、4時間、6時間、8時間反応させた。反応終了後、7-AADによる染色方法に記載した方法で測定を行い、FlowJoソフトウェアで解析し、細胞傷害活性率(%Lysis)を算出した。
(10-1) 高活性NK細胞の培養方法、回収方法1と回収方法2に記載した手順にて得られた高活性NK細胞の生細胞数をカウントし1x107 cells/mL(1.5mL tube。回収方法1、すなわち回収時にPBSで洗浄する場合)、4x107 cells/mL(5mL vial。回収方法2、すなわち回収時にKBM501培地で洗浄する場合)となるようにSTEM-CELLBANKERで懸濁し、-80℃で凍結保存した。48時間以上凍結させた高活性NK細胞を室温で解凍した。解凍した細胞を、完全に溶けた直後、5分、10分、15分、20分、25分、30分、60分、120分、180分のポイントでPlasma-Lyte AまたはKBM501培地に10倍希釈し、180分まで室温で静置した。180分まで希釈したあと7-AADによる染色方法に記載した方法で測定を行い、FlowJoソフトウェアで解析した。
高活性NK細胞の培養方法、回収方法1と回収方法2に記載した手順にて得られた高活性NK細胞の生細胞数をカウントし1x107 cells/mL(1.5mL tube)、4x107 cells/mL(5mL vial)となるようにSTEM-CELLBANKERで懸濁し、-80℃で凍結保存した。48時間以上凍結させた高活性NK細胞を37℃、ウォーターバスで解凍した。完全に溶けた直後にPlasma-Lyte AまたはKBM501培地に10倍希釈し、室温で6時間まで静置した。希釈直後、1時間、2時間、3時間、6時間のポイントで1x105cellsを分取し、7-AADによる染色方法に記載した方法で測定を行い、FlowJoソフトウェアで解析した。
(12-1) 高活性NK細胞の培養方法、回収方法2に記載した手順にて得られた高活性NK細胞の生細胞数をカウントし4x107 cells/mLとなるようにSTEM-CELLBANKERで懸濁し、-80℃で凍結保存した。48時間以上凍結させた高活性NK細胞を37℃、ウォーターバスで解凍した。完全に溶けた直後に、Plasma-Lyte AをUltraPure Distilled Water (invitrogen、10977-015)にて希釈した80% , 50%, 10% Plasma-Lyte Aで10倍希釈し、それぞれ室温と37℃で3時間まで静置した。希釈直後、1時間、2時間、3時間のポイントで1x105cellsを分取し、7-AADによる染色方法に記載した方法で測定を行い、FlowJoソフトウェアで解析した。
12-1~3の条件では、解凍時に用いるPlasma-Lyte Aの成分はその1/10まで希釈することができ、その希釈に用いる液は生理食塩水でも蒸留水でもよかった。すなわち、解凍時に用いる液は、低張液や生理食塩水であっても良いことが分かった。
以上について、一覧表にまとめた。なお、下表中、時間に関し、「xx時間」と記載した場合を除き、単位は分である。また、温度に関し、「R.T.」は室温を表し、それ以外の場合は37℃である。Viabilityに関し、Aは70%以上、Bは50%以上70%未満、Cは50%未満を表し、-は評価していないことを表す。活性に関し、Aは70%以上、Bは50%以上70%未満、Cは50%未満を表し、-は評価していないことを表す。評価がAまたはBであれば目的が達成されたといえる。
Claims (10)
- 以下の工程を含む、細胞の処理方法:
(1)体外で活性化した細胞を、細胞培養用の培地で回収し;
(2)回収した細胞を凍結保存のための液に懸濁し;
(3)懸濁した細胞を、凍結する。 - 工程(1)が、胆汁酸およびフェニル酪酸からなる群より選択されるいずれかを添加した培地による処理を含む、請求項1に記載の方法。
- さらに以下の工程を含む、請求項1または2に記載の方法:
(4)凍結保存した細胞を解凍し、解凍した細胞を解凍溶媒Iに懸濁する。 - 解凍溶媒Iが、以下を含む水溶液である、請求項1~3のいずれか1項に記載の方法:
・塩化ナトリウム 9.00~108mM、
・グルコン酸ナトリウム 2.30~27.7mM、
・酢酸ナトリウム 2.70~32.5mM、
・塩化カリウム 0.496~5.96mM、および
・塩化マグネシウム 0.148~1.78mM。 - 解凍溶媒Iが、以下の少なくとも1つを満たす、請求項1~4のいずれか1項に記載の方法:
・カルシウムイオンを0.423mM以上の濃度で含まない、
・グルコースを5.55mM以上の濃度で含まない、および
・乳酸塩を27.7mM以上の濃度で含まない。 - 以下を含む、高活性NK細胞を懸濁するための液:
・塩化ナトリウム 9.00~108mM
・グルコン酸ナトリウム 2.30~27.7mM
・酢酸ナトリウム 2.70~32.5mM
・塩化カリウム 0.496~5.96mM
・塩化マグネシウム 0.148~1.78mM - 凍結保存のための液に懸濁して凍結された高活性NK細胞を懸濁するためのものである、請求項6に記載の液。
- 高活性NK細胞、
凍結保存のための液、および
請求項6に記載された液
を含む、医薬組成物。 - 以下の工程を含む、細胞を含む医薬組成物の製造方法:
(1)体外で活性化した細胞を、細胞培養用の培地で回収し;
(2)回収した細胞を凍結保存のための液に懸濁し;
(3)懸濁した細胞を、凍結する。 - 工程(1)が、胆汁酸およびフェニル酪酸からなる群より選択されるいずれかを添加した培地による処理を含む、請求項9に記載の製造方法。
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP21765044.9A EP4151717A4 (en) | 2020-03-02 | 2021-03-02 | METHOD FOR TREATING HIGHLY ACTIVE NK CELLS |
KR1020227033295A KR20220148233A (ko) | 2020-03-02 | 2021-03-02 | 고활성 nk 세포의 처리 방법 |
AU2021230860A AU2021230860A1 (en) | 2020-03-02 | 2021-03-02 | Method for treating highly active NK cells |
CN202180018428.7A CN115279887A (zh) | 2020-03-02 | 2021-03-02 | 高活性nk细胞的处理方法 |
US17/908,472 US20230109717A1 (en) | 2020-03-02 | 2021-03-02 | Method for treating highly active nk cells |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020035297A JP2021136883A (ja) | 2020-03-02 | 2020-03-02 | 高活性nk細胞の処理方法 |
JP2020-035297 | 2020-03-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021177279A1 true WO2021177279A1 (ja) | 2021-09-10 |
Family
ID=77614337
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2021/007863 WO2021177279A1 (ja) | 2020-03-02 | 2021-03-02 | 高活性nk細胞の処理方法 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20230109717A1 (ja) |
EP (1) | EP4151717A4 (ja) |
JP (2) | JP2021136883A (ja) |
KR (1) | KR20220148233A (ja) |
CN (1) | CN115279887A (ja) |
AU (1) | AU2021230860A1 (ja) |
TW (1) | TW202140770A (ja) |
WO (1) | WO2021177279A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023038037A1 (ja) | 2021-09-08 | 2023-03-16 | 株式会社ガイアバイオメディシン | 細胞の処理方法 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002233356A (ja) | 2000-12-04 | 2002-08-20 | Human Tekku:Kk | 細胞の保存液および該保存液を用いた細胞の保存方法 |
JP2006230396A (ja) | 2004-10-12 | 2006-09-07 | Nipro Corp | 細胞保存液 |
WO2011021618A1 (ja) | 2009-08-19 | 2011-02-24 | タカラバイオ株式会社 | 細胞の保存方法 |
JP2018193303A (ja) | 2017-05-12 | 2018-12-06 | 米満 吉和 | 高活性nk細胞、およびその利用 |
JP2019170176A (ja) | 2018-03-27 | 2019-10-10 | 株式会社ガイアバイオメディシン | ケモカインレセプターと細胞接着分子を発現するcd3陰性細胞の集団、およびその利用 |
JP2020518260A (ja) * | 2017-05-04 | 2020-06-25 | メゾブラスト・インターナショナル・エスアーエールエル | 向上した免疫抑制作用を有する間葉系前駆または幹細胞 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103097520B (zh) * | 2010-07-13 | 2017-12-05 | 人类起源公司 | 产生自然杀伤细胞的方法 |
WO2014083133A1 (en) * | 2012-11-29 | 2014-06-05 | Cellectis Sa | Improved methods for producing mammalian pluripotent stem cell-derived endodermal cells |
WO2016122014A1 (ko) * | 2015-01-27 | 2016-08-04 | 한국생명공학연구원 | 자연살해세포의 대량생산 방법 및 상기 방법으로 수득된 자연살해세포의 항암제로서의 용도 |
US20180346877A1 (en) * | 2015-10-15 | 2018-12-06 | Celularity, Inc. | Natural killer cells and ilc3 cells and uses thereof |
CA3070739A1 (en) * | 2016-07-22 | 2018-01-25 | Tissue Testing Technologies Llc | Enhancement of cell cryopreservation with glycolipids |
JP2019024418A (ja) * | 2017-07-31 | 2019-02-21 | 公立大学法人大阪府立大学 | 選択分離用培地 |
-
2020
- 2020-03-02 JP JP2020035297A patent/JP2021136883A/ja active Pending
-
2021
- 2021-03-02 KR KR1020227033295A patent/KR20220148233A/ko unknown
- 2021-03-02 US US17/908,472 patent/US20230109717A1/en active Pending
- 2021-03-02 CN CN202180018428.7A patent/CN115279887A/zh active Pending
- 2021-03-02 EP EP21765044.9A patent/EP4151717A4/en active Pending
- 2021-03-02 WO PCT/JP2021/007863 patent/WO2021177279A1/ja unknown
- 2021-03-02 TW TW110107331A patent/TW202140770A/zh unknown
- 2021-03-02 AU AU2021230860A patent/AU2021230860A1/en active Pending
-
2023
- 2023-07-24 JP JP2023120214A patent/JP2023126695A/ja active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002233356A (ja) | 2000-12-04 | 2002-08-20 | Human Tekku:Kk | 細胞の保存液および該保存液を用いた細胞の保存方法 |
JP2006230396A (ja) | 2004-10-12 | 2006-09-07 | Nipro Corp | 細胞保存液 |
WO2011021618A1 (ja) | 2009-08-19 | 2011-02-24 | タカラバイオ株式会社 | 細胞の保存方法 |
JP2020518260A (ja) * | 2017-05-04 | 2020-06-25 | メゾブラスト・インターナショナル・エスアーエールエル | 向上した免疫抑制作用を有する間葉系前駆または幹細胞 |
JP2018193303A (ja) | 2017-05-12 | 2018-12-06 | 米満 吉和 | 高活性nk細胞、およびその利用 |
JP2019170176A (ja) | 2018-03-27 | 2019-10-10 | 株式会社ガイアバイオメディシン | ケモカインレセプターと細胞接着分子を発現するcd3陰性細胞の集団、およびその利用 |
Non-Patent Citations (3)
Title |
---|
LEONG JW ET AL., BIOL. BLOOD MARROW TRANSPLANT, vol. 20, 2014, pages 463 - 473 |
LIU E. ET AL., N. ENGL. J. MED., vol. 382, 2020, pages 545 - 53 |
See also references of EP4151717A4 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023038037A1 (ja) | 2021-09-08 | 2023-03-16 | 株式会社ガイアバイオメディシン | 細胞の処理方法 |
Also Published As
Publication number | Publication date |
---|---|
JP2021136883A (ja) | 2021-09-16 |
US20230109717A1 (en) | 2023-04-13 |
KR20220148233A (ko) | 2022-11-04 |
EP4151717A1 (en) | 2023-03-22 |
CN115279887A (zh) | 2022-11-01 |
JP2023126695A (ja) | 2023-09-07 |
TW202140770A (zh) | 2021-11-01 |
EP4151717A4 (en) | 2024-04-17 |
AU2021230860A1 (en) | 2022-09-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3027738B1 (en) | Mscs in the treatment of inflammatory pulmonary diseases | |
RU2756561C2 (ru) | Среда для формирования колоний и её применение | |
JP7144872B2 (ja) | ヒトリンパ球細胞培養用無血清培地 | |
US9956249B2 (en) | Compositions and methods for expansion of embryonic hematopoietic stem cells | |
JP2013523823A (ja) | 胎盤幹細胞を用いるサルコイドーシスの治療 | |
JP2022088551A (ja) | 増殖造血幹細胞/前駆細胞集団の利用 | |
Finkielsztein et al. | Human megakaryocyte progenitors derived from hematopoietic stem cells of normal individuals are MHC class II-expressing professional APC that enhance Th17 and Th1/Th17 responses | |
KR20220038450A (ko) | 면역치료를 위한 nk 세포 조성물 및 제제 및 이의 생산 방법 | |
AU2022204899A1 (en) | Methods and compositions for stem cell transplantation | |
JP2023126695A (ja) | 高活性nk細胞の処理方法 | |
Buchanan et al. | Cryopreservation of human hematopoietic stem and progenitor cells loaded with trehalose: transient permeabilization via the adenosine triphosphate-dependent P2Z receptor channel | |
US20230141224A1 (en) | Fibroblast mediated expansion and augmentation of immune regulatory cells for treatment of acute respiratory distress syndrome (ards) | |
WO2020251046A1 (ja) | 医薬組成物 | |
WO2023038037A1 (ja) | 細胞の処理方法 | |
KR100569609B1 (ko) | 세포면역치료제의 제조를 위한 림프구 장기 보관 방법 | |
US20220218759A1 (en) | Compositions and methods for improving treatment outcomes for patients having hematological malignancies using an expanded stem cell product | |
Landum | Targeting a bicarbonate transporter in pancreatic cancer overcomes immunosuppression | |
Delgado et al. | Uses of mesenchymal stem cells | |
Zhou et al. | Hetrombopag, a Thrombopoietin Receptor Agonist, Protects Cardiomyocyte Survival from Oxidative Stress Damage as an Enhancer of Stem Cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21765044 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2021230860 Country of ref document: AU Date of ref document: 20210302 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20227033295 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021765044 Country of ref document: EP Effective date: 20221004 |